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Metabolism-oriented Lead Optimization of Propargyl-
linked DHFR Inhibitors 
Wangda Zhou, Ph.D. 
University of Connecticut, 2014 
Dihydrofolate reductase (DHFR), a key enzyme within folate biosynthetic pathway, has 
been a popular drug target for over six decades.  Trimethoprim (TMP) is the only FDA 
approved antibacterial DHFR inhibitor and remains clinically important.  However, 
acquired resistance by point mutations and natural enzymatic insensitivity limit its use.   
A library of novel propargyl-linked antifolates targeting DHFR from MSRA, Candida and 
Klebsiella species was developed.  Early lead propargyl-linked antifolates were proven 
potent antibacterial and antifungal agents.  Much effort was placed on evaluating the 
metabolism properties.  A strategy of incorporating crystallographic insight and 
experimental evaluation of structure-activity relationships (SAR) to guide new 
compound generation was explored to optimize the drug likeliness while maintaining 
high antimicrobial potency.  Exciting compounds with excellent antibacterial activity 
(MIC = 0.02 µg/mL against MRSA), moderate metabolic stability (t1/2 = 99 min), low CYP 
inhibition (IC50 > 50 µM against CYP3A4 and CYP2D6) were designed and generated.  
These studies will lead to identification of promising candidate compounds that would 
be ready for further translational development.    
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Chapter 1 
DHFR inhibitors as antimicrobial agents 
1.1. Introduction 
The folate biosynthetic pathway is responsible for the generation of deoxythymidine 
monophosphate (dTMP), purine nucleotides and the amino acids methionine and 
histidine in many species [1].  Inhibition of the folate pathway interrupts DNA replication 
and suppresses cell proliferation.  Essential enzymes in this pathway have been popular 
drug targets since the 1930s [2]. 
1.2. DHFR and folate biosynthesis  
Human folate biosynthesis starts from folic acid dietary uptake.  Once consumed, folic 
acid is reduced to dihydrofolate (DHF) and subsequently tetrahydrofolate (THF) by 
dihydrofolate reductase (DHFR), coupled with oxidization of cofactor NADPH.  With the 
presence of serine, THF is then converted to 5, 10-methylene tetrahydrofolate, which 
acts as C1 donor for dTMP, purines, histidine and methionine generation (Fig. 1).  
In contrast, bacteria, fungi and protozoa cannot sufficiently obtain environmental folate.  
These organisms pose a multi-step endogenous folate synthesis process which converts 
readily available guanosine triphosphate (GTP) to DHF.  With the de novo DHF 
biosynthesis, nucleotides and amino acids are then generated with the same enzymatic 
process as in humans. 
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Figure 1.  Folate biosynthetic pathway.  The bacterial, fungal and protozoal specific 
biosynthetic reactions are highlighted in green while the essential pathway in all species 
is shown in yellow.  Products of the path are shown in blue.   
 
1.3. DHFR inhibitors and TMP resistance 
For over six decades, DHFR inhibitors have been successfully used as antiprotozoal 
(cycloguanial, pyrimethamine), anticancer (methotrexate) and antibacterial 
(trimethoprim) therapeutics [3-5].  Despite the great success of DHFR inhibitors, 
trimethoprim (TMP) is the only FDA approved antibacterial antifolate and remains 
clinically important.  However, acquired resistance by point mutations and natural 
resistant strains limit its use. 
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Figure 2.  Structures of clinically used DHFR inhibitors 
 
1.3.1 TMP resistance in MRSA 
Staphylococcus aureus is a leading cause of bloodstream infections (BSI), skin and soft 
tissue infections (SSTI) and pneumonia worldwide [6].  Shortly after methicillin was 
introduced for S. aureus treatment, the first methicillin-resistant Staphylococcus aureus 
(MRSA) isolate was reported in England in 1961[7].  MRSA appeared in the US in 1968 [4] 
and had emerged by the early 1980s [8].  While MRSA remains a leading cause of 
hospital acquired infections, the incidence of community-acquired MRSA (CA-MRSA) has 
also rapidly increased since 1997, reaching over 14 million cases by 2005[9].  CA-MRSA 
isolates are likely susceptible to Bactrim (a TMP and sulfamethoxazole combination) [10], 
which is recommended as a first-line treatment for outpatient SSTIs [11-14]. 
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TMP resistance in S. aureus was first found to be mediated by plasmid pSK1 in Australia 
[15].  The pSK1 plasmid was later shown to be encoded with the highly resistant type S1 
DHFR [16].  Three years later, a similar TMP-resistant plasmid pABU1 was found in 
Switzerland [17].  The worldwide dissemination was explained through the spread of 
transposon Tn4003 [17-18].  Investigation of an international collection of strains 
suggested that 28% of MRSA strains are TMP-resistant [19].  Comparing to high-level 
resistance mediated transposons, the more common form of resistance involves 
mutations in the chromosomal DHFR gene, yielding intermediate levels of resistance 
(~250-fold).  A common amino acid mutation from Phe to Tyr at position 98, which 
creates a greater than 70-fold loss of affinity for TMP, is believed to be the origin of TMP 
resistance in S. aureus [20].  High-resolution crystal structures of wild-type and F98Y 
mutant S. aureus DHFR bound to ligands explain that the decreased TMP binding may be 
due to the loss of conserved hydrogen bonding [20] or the displacement of cofactor 
NADPH [21].   
1.3.2 TMP resistance in E. coli 
Urinary tract infections (UTIs), primarily caused by gram-negative Enterobacteriaceae  
(for example Escherichia coli) [22], are among the most common bacterial infections in 
the US [23].  TMP-SMX is recommended as first-line medication for UTIs [24].  However, 
TMP-SMX resistance in E. coli substantially increased from 17.9% in 2000 to 24.2% in 
2010 [25], making this combination therapy a poor choice for pediatric UTIs in many 
geographical areas [26].  TMP resistance in E. coli is caused by the acquisition of 
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modified dfr genes that carry out the catalytic function but are naturally resistant to the 
drug.  About twenty different resistant dfr genes, found in Class 1 and Class 2 integrons 
[27], have been isolated [28-29].  dfrA1 and dfrA17 are found to be the most prevalent 
in clinical isolates [30].  The worldwide dissemination of TMP resistance in E. coli is 
primarily caused by horizontal gene transfer, while clonal expansion only plays a minor 
role [31-32].  
1.3.3 Species with a natural insensitivity to TMP 
Interestingly, despite the conservation of the sequence of DHFR over a long 
evolutionary period, TMP is selective for certain bacteria such as S. aureus and E. coli 
but does not inhibit the DHFR enzymes of many other important pathogenic bacteria.  
While its inability to inhibit human DHFR is an advantage in its use as an antimicrobial 
agent, it also does not inhibit DHFR from several pathogenic eukaryotic species such as 
fungi or protozoa, limiting its range of coverage.   
Cryptosporidium spp, a parasitic protozoan with few effective therapeutics, can cause 
diarrhea lasting weeks in immunocompetent patients or severe enteritis in children, 
elderly and immunocompromised patients [33]. Cryptosporidium hominis is naturally 
resistant to TMP, exhibiting weak inhibition of the DHFR enzyme (IC50 = 14 µM) [34].  
Bacillus anthracis, the bacterium responsible for anthrax, is one of the most serious 
organisms used as a biological weapon [35].  B. anthracis is also naturally resistant to 
TMP due to minimal inhibition of DHFR (IC50 = 77 µM) [36].  Candida species are the 
fourth ranked nosocomial bloodstream pathogen in the US and have the highest crude 
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mortality at 40% [37].  Among all the hospital-acquired BSI pathogenic Candida spp, C. 
albicans comprised 45% of the isolates, followed by C. glabrata at 24% [38].  TMP is an 
ineffective antifungal agent owing to lack of enzymatic inhibition (IC50 = 42 µM) for C. 
albicans [39] and (IC50= 7 µM) for C. glabrata [40]. 
1.4. Conclusions 
DHFR as one of the key enzymes from folate biosynthetic pathway has been an 
important drug target for more than sixty years.  TMP, the sole FDA approved 
antibacterial antifolate, remains clinically important.  Natural enzyme insensitivity and 
acquired resistance limit TMP usage.  During the past two decades, many attempts have 
been made to develop TMP derivatives that are effective against TMP-resistant species 
and naturally insensitive species [41-44].  Novel antimicrobial agents targeting DHFR 
from TMP resistant strains would provide a much needed therapeutic fighting against 
infectious diseases.  
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Chapter 2 
Development of novel propargyl-based DHFR inhibitors 
2.1. Introduction 
Over the past several years, a library of novel DHFR inhibitors have been designed and 
synthesized under a robust collaboration between the laboratories of Drs. Amy 
Anderson and Dennis Wright.  These DHFR inhibitors are characterized by a conserved 
diaminopyrimidine ring linked through a propargylic spacer to a variable hydrophobic 
domain.  Early lead compounds in this library exhibit promising inhibition of DHFR and 
antimicrobial activity against Staphylococcus aureus [1], Candida glabrata [2] and 
Candida albicans [3]. 
2.2. Development of propargyl-linked antifolates 
The need for therapeutic agents against trimethoprim (TMP) insensitive species such as 
protozoa Cryptosporidium and Toxoplasma inspired the development of a series of 
novel DHFR inhibitors that feature an acetylenic linker [4].  Crystallographic insight of 
DHFR from Cryptosporidium hominis and Toxoplasma gondii suggested that extended 
TMP analogues with a three-carbon propargylic linkage between the diaminopyrimidine 
and phenyl rings should improve ligand and protein interaction.  Initial docking of TMP 
and early propargyl-linked antifolate UCP100A (Fig 1.) into the binding site of C. hominis 
DHFR (ChDHFR) illustrated that with prolonged propargylic linker, trimethoxyphenyl 
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moiety of UCP100A was deeper positioned into the hydrophobic pocket comparing to 
TMP.  
 
Figure 1. a, TMP docked into the active site of ChDHFR.  b, UCP100A docked into the 
active site of ChDFHR 
 
Experimental analysis of ChDHFR inhibition also confirmed that first generation lead 
compound UCP111A (IC50 = 38 nM) is over 300 folds more potent than TMP (IC50=14 µM) 
(Scheme 1.).  The generation of UCP111D, a lead compound with phenyl substitution at 
distal position, showed further improved potency with an IC50 of 1.8 nM.  With this 
proof of concept, extensive efforts have been made to characterize and optimize 
propargyl-lined DHFR inhibitors as effective therapeutic agents against Bacillus anthracis, 
Staphylococcus aureus, Klebsiella and Candida species.  
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Scheme 1.  Progression of propargyl-linked antifolates effective against ChDHFR  
 
2.3. Evolution of propargyl-based antifolates 
The first generation propargyl-linked DHFR inhibitors featuring a pyrimidine ring with 
methyl or ethyl substituted C6 position and a single substitute benzene ring adjacent to 
the propargyl position.  Lead compounds in this generation exhibited promising 
enzymatic inhibitory activity, however, they are not active at the cellular level [5].  
Crystal structures of ChDHFR complexed with these early propargyl-linked antifolates 
suggested that potency can be gained by adding hydrophobic interaction with the 
second hydrophobic pocket [1, 3, 6].  With this hypothesis, the second generation 
inhibitors with a substituted biphenyl moiety were designed and synthesized. 
 
 Scheme 2.  Progression of compounds targeting S. aureus DHFR. 
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These second generation compounds are excellent inhibitors of both TMP-sensitive and 
resistant DHFR enzymes.  Moreover, lead compounds exhibited marked antibacterial [7] 
and antifungal activity [8].  Nevertheless, with increased molecular weight and 
hydrophobicity, most compounds in this series have poor water solubility [9].  It is well 
accepted that water solubility is critical drug likeliness parameter which affects both 
drug distribution and metabolism [10-11].  Therefore, with the goal to balance the 
compound polarity and improve water solubility, a series of analogues with heterocycles 
substituted at para of the adjacent phenyl ring were designed and synthesized as the 
third generation of inhibitors.  Lead compounds in the third generation inhibitors are 
generally equal or more potent than the biphenyl inhibitors in both enzymatic and cell 
based inhibitory assays [7, 12].  UCP1006, a key compound in the heterocyclic series, 
also showed encouraging efficacy against mutant SaDHFR and TMP resistant MRSA 
stains [13].  
 
Scheme 3.  Compounds evolution against DHFR from C. albicans and C. glabrata. 
 
2.4. Conclusions 
Novel antifolates characterized with a rare acetylenic scaffold targeting TMP insensitive 
pathogenic DHFR from MRSA, C. albicans and C. glabrata were developed.  Lead 
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biphenyl series compounds exhibited potent enzymatic inhibition and antiproliferative 
activity.  To improve the water solubility and drug likeliness of these compounds, more 
polarity balanced heterocyclic compounds were synthesized.  Lead compounds in this 
generation are potent MSRA and fungal inhibitors.  To move this drug discovery effort 
forward, more detailed drug like properties of propargyl-linked antifolates will be 
explored.  
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Chapter 3 
Initial physicochemical and stability evaluation of DHFR inhibitors 
3.1. Introduction 
Drug discovery and development has become increasingly risky, costly and time 
inefficient [1].  Estimates for the average cost and cycle time of bringing a new drug to 
market is 1.8 billion dollars and 13.5 years [2].  One of the biggest challenges of drug 
discovery is high attrition rate.  In the early 1990s, adverse drug metabolism and 
pharmacokinetics (DMPK) properties ranked first and accounted for about 40% of all 
drug attrition [3].  This number dropped to less than 10% in 10 years with early DMPK 
screening and optimization [4].  Detailed understanding of how structure-property 
relationships (SPR) relate to major DMPK weaknesses is critical to support lead 
identification and optimization for pharmacological potency [5].   
Drug metabolism research plays a particularly important role in the hit-to-lead stage of 
drug discovery, where many new chemical entities exhibit poor metabolic stability in 
liver microsomes [6].  Throughout the early drug discovery stage, in vitro drug 
metabolism assays mainly focus on the role of cytochrome P450s (CYP), which is 
responsible for about 80% of known oxidative drug metabolism reactions [7].  
Microsomal stability assay using liver microsomes is commonly used and recommended 
to be applied to all discovery compounds as soon as they are synthesized [8].  
Quantitative metabolic stability data are often used to evaluate the extent of 
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metabolism, rank order compounds for in vivo studies and prioritize discovery activities 
[9].  A single-point metabolism assay with 15 min incubation time would allow accurate 
measurement of highly unstable compounds (t1/2 <5 min) with a proper detection upper 
limit of 30 min [10].  Concerns of microsomal stability decrease at t1/2 greater than 30 
min.  CYP inhibition is the major cause of drug-drug interactions and early CYP inhibition 
measurement would provide warning of protential safety liability [11].  CYP inhibition 
data is useful to select lead compounds and develop structure-CYP inhibiton property 
relationships, which enables the medicinal chemist to overcome CYP inhibition by 
structural modification [12].  Evaluation of other drug-like properties (permeability, 
solubility, solution staibliy etc.) should be also considered based on the scafold of a 
compound series [13].   
3.2. Drug-like properties evaluation of propargyl-linked antifolates 
3.2.1 Introduction   
The novel propargyl-linked antifolates developed in the Anderson/Wright labs are 
potent antimicrobial against MRSA and Candida spp [14-16].  Preliminary 
physicochemical evaluation suggested that changes in the lead compounds in the 
biphenyl series greatly increased hydrophobicity and imbalanced the polarity of the 
molecule.  Initial assessment also suggested that these lead compounds have poor 
water solubility.  It is important to understand the detailed physicochemical properties 
and to examine the drug likeliness of the lead compounds.  In this chapter, membrane 
permeability, kinetic water solubility, solution stability and metabolic stability of lead 
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propargylic-linked DHFR inhibitors will be described.  By incorporating the 
crystallographic structural insight, lead compounds with better absorption, disposition, 
metabolism and excretion (ADME) properties that maintain potency will be developed. 
3.2.2 Membrane permeability testing of lead compounds 
A parallel artificial membrane permeability assay (PAMPA) was used to evaluate the 
membrane permeability of lead propargyl-linked antifolates [17].  The second 
generation biphenyl serial propargyl-linked antifolates generally exhibited high 
hydrophobicity; therefore, compounds with different polarity functional groups 
(UCP114B, UCP113A and UCP10003) were chosen for PAMPA testing, with TMP and 
dihydrofolate (DHF) as controls.  Compounds UCP1003 and UCP114B, highlighted with 
propargylic methyl and hydrophobic substitutions at the adjacent phenyl ring, both 
show high permeability at 45 and 21 *10-6 cm/sec (Table 1.), equivalent to 10 and 4.7 
fold higher than TMP control, respectively.  In contrast, compound UCP113A, 
characterized with a polar hydroxyl group at the propargyl position, cannot pass through 
the artificial membrane showing no permeability, similar to the negative control, DHF.  
Combined with the fact that most potent lead compounds contain a hydrophobic 
biphenyl or phenyl-heterocyclic system adjacent to acetylenic linker, membrane 
permeability seems to be a minor ADME weakness for this class of antifolates.    
Table 1. Structure and permeability of propargyl-linked antifoltes 
Compounds Structure 
Permeability 
(10-6 cm/sec) 
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UCP114B 
 
45.0 
UCP113A 
 
0 
UCP1003 
 
20.9 
DHF 
 
0 
TMP 
 
4.5 
 
3.2.3 Kinetic solubility evaluation of biphenyl series inhibitors 
Introduction of the biphenyl functional group better accommodated the secondary 
hydrophobic binding pocket from DHFR and increased potency.  However, it also sharply 
increased the hydrophobicity and decreased water solubility of the compounds.  To 
evaluate and improve the kinetic water solubility without losing potency, the structure-
20 
 
activity relationship (SAR) of lead compounds were carefully evaluated.  A crystal 
structure of lead biphenyl compound UCP111D bound to C. glabrata DHFR (Fig 1.) 
revealed that the meta and para positions of the distal phenyl ring are generally solvent 
exposed [18].  Therefore, substitution of more polar functional groups at this area is 
likely to be tolerated.  
a, 
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b, 
 
Figure 1. a, UCP111D bound to C. glabrata DHFR (from Protein Data Bank identifier 3EEJ), 
b, and structure of lead compound UCP111D. 
 
With this hypothesis, analogues with six member meta or para heterocyclic rings at the 
distal position were designed and synthesized.  The LogD values at pH7.4 were 
calculated in silico using software ChemAxon and the experimental solubility were also 
determined. 
With a substitution of morpholine or pyridine, UCP1004 and UCP1006 (Fig 2.) exhibited 
reduced cLogD7.4 values at 2.90 and 3.44, respectively.  Experimentally tested kinetic 
water solubility with the presence of 0.02% hydroxypropyl methylcellulose (HPMC) also 
confirmed the solubility increase from 20 µg/mL for UCP111D to over 80 µg/mL and 40 
µg/mL, respectively.  The use of HPMC as a stabilizing agent in solubility testing 
effectively prevented compound precipitation in solution and eliminated day to day 
variation.  More impressively, both UCP1004 and UCP1006 were potent against S. 
aureus DHFR with IC50 values of 19 nM and 26 nM, respectively.  In addition, UCP1006 
also exhibited excellent antibacterial activity against S. aureus with MIC = 0.08 µg/ml 
and was considered as key lead compound in the heterocyclic series.  UCP1004 was not 
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active against MRSA, likely due to the poor bacterial membrane penetration and 
therefore not further developed.   
 
Figure 2. Structures and solubility values of propargyl-linked antifolates 
 
3.2.4 Solution and metabolic stability analysis of lead compounds 
To investigate the solution and metabolic stability of the lead propargyl-linked 
antifolates, compounds UCP1005, UCP1006, UCP1015 and UCP1021 were chosen for 
analysis.  The structure of testing compounds show as figure 3.  The testing compounds 
feature substitution patterns at C6 position at the pyrimidine ring (R1, UCP1005 versus 
UCP1006), propargylic position (Rp, UCP1006 versus UCP1015) and methoxyl 
substitution position (R2 and R3, UCP1015 versus UCP1021).  
The set of four testing compounds was first evaluated for solution stability in simulated 
intestinal fluid (pH7.4), simulated gastric fluid (pH1.2) and water at 37 °C for 24 
hours[19].  Testing concentration was 5 µg/mL. The HPLC-UV assessment showed that 
there is no change in area under curve (AUC) or peak shape after incubation in any of 
the fluids.  This suggested that compounds are stable under all tested conditions.  
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Figure 3. Structures of UCP1005, UCP1006, UCP1015 and UCP1021 
 
To evaluate the phase I metabolic stability, all four compounds were incubated for 1 
hour with commercially available mouse liver microsomes (MLM) with the presence of 
an NADPH regenerating system [20].  The percentage of parent compound remaining 
after incubation relative to the starting concentration was calculated using a standard 
curve.  The metabolic half-life was calculated following a first order kinetics.  
Compounds UCP1005 and UCP1006, which vary in substitution at the R1 position both 
exhibit moderate and similar stability with values of 33 and 29% remaining, respectively.  
However, analogue UCP1015 with a hydrogen at propargylic position (Rp) showed 
sharply reduced metabolic stability with only trace amount of parent compound left 
after 1 hour.  Surprisingly, substituting the methoxy group from R2 to R3 position 
(UCP1021) retained the metabolic stability resulting 27% of the parent remaining after 
incubation.  Collectively, it is evident that the metabolic stability of these compounds is 
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extremely sensitive to substitutions at the propargylic position and the 2’ and 3’ 
positions on the adjacent phenyl ring [18].   
Table 2. Metabolic half-life of propargyl-linked antifolates 
Compound 
Percentage Remaining 
 after 1h  
Half-Life 
(min) 
UCP1005 34 38 
UCP1006 29 34 
UCP1015 0 <10 
UCP1021 27 31 
 
3.3. Conclusions 
Previous studies have validated that propargyl-linked antifolates are potent inhibitors 
against MRSA, C. albicans and C. glabrata.  Initial physicochemical property and solution 
stability evaluation suggested that lead DHFR inhibitors are low to moderately water 
soluble, highly membrane permeable and stable in various simulated solutions.  
Metabolic stability studies indicated that some lead propargyl-linked antifolates are 
quickly metabolized by MLM.  In addition, microsomal stability is highly sensitive to 
substitutions at the propargylic and adjacent phenyl positions.  To further understand 
and potentially improve the ADME properties of propargyl-linked antifolates, primary 
routes of metabolism will be characterized and strategies to reduce hepatic metabolism 
will be explored. 
25 
 
3.4. References 
1. Orloff, J., et al., The future of drug development: advancing clinical trial design. Nat Rev 
Drug Discov, 2009. 8(12): p. 949-57. 
2. Paul, S.M., et al., How to improve R&D productivity: the pharmaceutical industry's grand 
challenge. Nat Rev Drug Discov, 2010. 9(3): p. 203-14. 
3. Kennedy, T., Managing the drug discovery/development interface. Drug Discov Today, 
1997. 2(10): p. 436-444. 
4. Kola, I. and J. Landis, Can the pharmaceutical industry reduce attrition rates? Nat Rev 
Drug Discov, 2004. 3(8): p. 711-5. 
5. Ballard, P., et al., The right compound in the right assay at the right time: an integrated 
discovery DMPK strategy. Drug Metab Rev, 2012. 44(3): p. 224-52. 
6. Stepan, A.F., et al., Evaluating the differences in cycloalkyl ether metabolism using the 
design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular 
pairs analysis. J Med Chem, 2013. 56(17): p. 6985-90. 
7. Wienkers, L.C. and T.G. Heath, Predicting in vivo drug interactions from in vitro drug 
discovery data. Nat Rev Drug Discov, 2005. 4(10): p. 825-33. 
8. Kerns, E.H. and D. Li, Drug-like Properties: Concepts, Structure Design and Methods. 
Academic Press;, 2008. 
9. Ansede, J.H. and D.R. Thakker, High-throughput screening for stability and inhibitory 
activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci, 
2004. 93(2): p. 239-55. 
10. Di, L., et al., Experimental design on single-time-point high-throughput microsomal 
stability assay. J Pharm Sci, 2004. 93(6): p. 1537-44. 
11. Rodrigues, A.D. and J.H. Lin, Screening of drug candidates for their drug--drug 
interaction potential. Curr Opin Chem Biol, 2001. 5(4): p. 396-401. 
12. Kerns, E.H. and L. Di, Pharmaceutical profiling in drug discovery. Drug Discov Today, 
2003. 8(7): p. 316-23. 
13. Di, L. and E.H. Kerns, Profiling drug-like properties in discovery research. Curr Opin Chem 
Biol, 2003. 7(3): p. 402-8. 
14. Viswanathan, K., et al., Toward new therapeutics for skin and soft tissue infections: 
propargyl-linked antifolates are potent inhibitors of MRSA and Streptococcus pyogenes. 
PLoS One, 2012. 7(2): p. e29434. 
15. Paulsen, J.L., et al., Structural analysis of the active sites of dihydrofolate reductase from 
two species of Candida uncovers ligand-induced conformational changes shared among 
species. Bioorg Med Chem Lett, 2013. 23(5): p. 1279-84. 
16. Liu, J., et al., Towards new antifolates targeting eukaryotic opportunistic infections. 
Eukaryot Cell, 2009. 8(4): p. 483-6. 
17. Kansy, M., F. Senner, and K. Gubernator, Physicochemical high throughput screening: 
parallel artificial membrane permeation assay in the description of passive absorption 
processes. J Med Chem, 1998. 41(7): p. 1007-10. 
18. Zhou, W., et al., Acetylenic linkers in lead compounds: a study of the stability of the 
propargyl-linked antifolates. Drug Metab Dispos, 2012. 40(10): p. 2002-8. 
19. Di, L. and E.H. Kerns, Solution stability--plasma, gastrointestinal, bioassay. Curr Drug 
Metab, 2008. 9(9): p. 860-8. 
20. Di, L., et al., High throughput microsomal stability assay for insoluble compounds. Int J 
Pharm, 2006. 317(1): p. 54-60. 
26 
 
Chapter 4 
Metabolite identification of lead propargyl-linked DHFR inhibitors  
4.1. Introduction 
Understanding the relation of structure-property relationship (SPR) to major drug 
metabolism and pharmacokinetics (DMPK) weaknesses is critical to support lead 
optimization for pharmacological potency [5].  Initial physicochemical and stability 
assessment of propargyl-linked DHFR inhibitors indicated that some lead compounds 
are associated with poor metabolic stability.  It is important to thoroughly investigate 
their metabolic routes.  
In this chapter, metabolites of lead compounds will be identified and characterized.  The 
distribution of major metabolites will be quantified.  The primary metabolites will also 
be also validated through synthesized standards.  SPR between leads and metabolic 
stability will be carefully analyzed and potent antifolates with increased metabolic 
stability will be designed, synthesized and evaluated.   
4.2. Metabolite identification and characterization 
Initial testing for lead compounds UCP1005, UCP1006, UCP1015 and UCP1021 indicated 
that the metabolic stability of these compounds is sensitive to substitutions at the 
propargylic and 2’ and 3’ positions at the adjacent phenyl ring.  The same set of four 
compounds was also chosen for metabolite identification.  Testing compounds at 10 
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µg/mL were incubated with MLM in the presence of a NADPH regenerating system for 
two hours.  The reactions were terminated by ice cold acetonitrile and the proteins 
were precipitated through centrifugation.  Samples were further purified and 
concentrated with a HLB Oasis column and analyzed with a LC-MS/MS [21].  Mass 
spectrometry results showed the presence of metabolic products at mass corresponding 
to M-14, M+16 and M+32 (where M is mono isotopic molecular weight).  For all four 
testing compounds, M-14 metabolites were easily assigned as the O-demethylation 
product at the 2’ or 3’ position at the adjacent phenyl ring.  Assignment of the M+16 
metabolites was difficult because of the multiple potential oxidation sites including 
open aromatic systems, the propargylic position, C6 benzylic position, the acetylenic 
linker, and the endocyclic basic nitrogens of the pyrimidine and pyridine systems.  To 
assign the major mono-oxidation metabolites, both mass spectrum analysis and organic 
synthesis approaches were attempted. 
 
Figure 1. Structure of UCP1030 
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Compound UCP1015 exhibited sharply reduced metabolic stability compared to 
UCP1006.  The two compounds feature variations of hydrogen and methyl groups at the 
propargylic position only.  Quantification of the major metabolites by area under curve 
(AUC) from LC-MS spectrum also indicated that the primary mono-oxidation for 
UCP1015 accounted for 70.5% of the total metabolites, which is significantly higher than 
the corresponding metabolite of UCP1006 (45.8%).  Considering the shorter half life, 
metabolism of UCP1015 through mono-hydroxylation is predicted to be much more 
than UCP1006. Incorporating the SAR assessment, the difference in metabolic stability 
of the two compounds may be explained by the proposal that oxidation of the 
unsubstituted propargyl carbon (UCP1015) to a secondary alcohol would occur faster 
than a methyl substituted carbon (UCP1006) to a tertiary alcohol.  With this hypothesis 
in mind, UCP1030 (as Fig 1.) was synthesized to match the major metabolite of UCP1015.  
However, the fragment pattern in LC-MS/MS of UCP1030 did not match any of the 
mono-oxidation metabolite of UCP1015.  Therefore, propargylic oxidation appeared not 
to be the major metabolic route for these compounds.  
Table 1. Metabolite distribution of lead propargyl-linked antifolates. Percentages based 
on total AUC. 
 
Compound 
 
Pyridyl N-
Oxidation (+16) 
 
Demethylation  
(-14) 
Oxidation on 
Pyrimidinyl 
Substructure 
(+16) 
 
Bis-Oxidation  
(+32) 
UCP1005 60%(M2-1) 16%(M2-2) 14%(M2-3) 10% 
UCP1006 45%(M3-1) 28%(M3-2) 26%(M3-3) 
<5%(M3-4) 
10% 
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UCP1015 71%(M7-1) 6%(M4-2) 5%(M7-3) 15% 
UCP1021 74%(M8-1) 20%(M8-2) 6%(M8-3) 2% 
 
Metabolites of compound UCP1021 provided helpful information for assigning 
biotransformation routes.  Three major metabolites identified are O-demethylation 
product (named M8-2, 19.7%) and two mono-oxidation products (M8-1 74.2% and M8-3 
6.3%).  The collision induced dissociation (CID) spectrum of the parent compound 
UCP1021 (noted as 8 in Scheme 1.) showed cleavage at either the a-b bond or the b-c 
bond, generating two primary fragments F1 and F2 (Scheme 1a.).  The ion F1 at m/z = 
198.1 was assigned as a benzylic cation, whereas ion F2 at m/z = 175.1 was assigned as 
the propargylic cation.  The appearance of either m/z = 198.1 fragment or m/z =175.1 
fragment in the CID spectrum of metabolite M8-1 or M8-3 was used to assign the 
oxidation position to either the F1 or the F2 moieties of the inhibitor.  The CID spectrum 
of the primary metabolite M8-1 showed a fragment at m/z = 175.1, indicating that the 
oxidation is on the 4-phenylpyridyl subunit.  The minor metabolite M8-3 shows the 
presence of the strong fragment at m/z = 198.1, signifying that the biaryl domain was 
unchanged and thus oxidation on the pyrimidine moiety.  Although the fragmentation 
pattern was also observed for other testing inhibitors UCP1005, UCP1006 and UCP1015, 
these diagnostic ions did not appear in the CID spectra of the metabolites.     
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Scheme 1. Diagnostic fragments derived from the ionization of compound 8 (UCP1021). 
 
Both C- and N-oxidation are possible biotransformation routes for propargyl-linker 
antifolates, generating pyrimidine-N-oxides, which was also observed for TMP [22], 
pyridine-N-oxides, as well as various phenols and alcohols.  The CID spectrum of 
pyridine-N-oxides derived from desloratodine [23] showed that two diagnostic 
fragments were generated by a loss of 17 and 18 mass units from the parent ion.  
Because similar fragmentation patterns were also observed for CID spectra of M3-1 (Fig 
3.) and M3-4 (two metabolites for UCP1006) and clearly not related by isotopic effects 
(estimated to be 22.8%), the formation of N-oxides as a major metabolic pathway 
seemed probable.  Whereas, the CID spectra of M3-3 showed two peaks with loss of 17 
and 18 mass units,  the integration is close to the expected isotopic effect (23%), 
therefore the presence of N-oxide cannot be unambiguously assigned.  In addition, the 
peaks associated with the N-oxides M3-1 and M3-4 eluted with retention time longer 
than that of the parent compounds, while the demethylation product M3-2 and the 
unassigned oxidation product M3-3 eluted with shorter retention times than the parent.  
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The difference in the retention time is likely due to the loss of one of the basic nitrogens, 
an effect that would be expected with acid mobile phase.  
To further verify the identity of these metabolites, synthetic standards of N-oxidation 
products were prepared.  It appeared that using controlled oxidation condition of 
UCP1006 with m-chloroperoxybenzoic acid at low temperature generated a mixture of 
three characteristic N-oxides, which were assigned as two regioisomeric pyrimidine-N-
oxides and the pyridine-N-oxide by nuclear magnetic resonance (NMR) (Fig 4.).   
a. 
 
b. 
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c. 
 
Figure 3. CID spectra of metabolites of UCP1006 a. M3-1, b. M3-3, and c. M3-4. 
 
Careful separation of the pyridine-N-oxide from the two pyrimidine-N-oxides was 
performed using HPLC.  LC-MS/MS assessment of the synthetic mixture and the 
metabolic products confirmed that two of the three chemical oxidation products exactly 
matched two of the metabolites formed during microsomal incubation.  Taken together, 
we were able to unambiguously assign the structure of M3-1 as the pyridine-N-oxide 
using both retention time and CID spectra.  Additionally, one of the two isomeric 
pyrimidine-N-oxide also matched with another minor metabolite M3-4.  The remaining 
mono-oxidation product (M3-3) has not been assigned, despite that the fragmentation 
pattern clearly suggested that the oxidation has occurred on the pyrimidine moiety of 
the inhibitor and likely to be the product of benzylic oxidation at C6 pyrimidine position.   
Using the retention time and CID spectrum, the remaining metabolites from testing 
compounds UCP1005, UCP1015 and UCP1021 were assigned on the basis of analogy to 
the metabolite identification process with UCP1006. Despite the difference in metabolic 
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stability, all three compounds are metabolized primarily through pyridine-N-oxidation. 
Only a trace amount pyrimidine-N-oxide was detected for these compounds. 
Metabolites M2-3, M7-3 and M8-3 appear to be oxidation products on the pyrimidine 
moiety, such as C6 side chain oxidation or hydroxylamine formation.   
 
 
Figure 4. Proton NMR spectra of UCP1006 and the associated pyridine-N-oxide.   
 
4.3. Metabolic stability improvement 
Combining the metabolic half-life and metabolite distribution results of compounds 
UCP1005, UCP1006, UCP1015 and UCP1021, substitutions at the propargylic position 
and the adjacent aromatic phenyl ring exhibits remote control influence on compound 
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metabolism on the distal sites.  Specifically, metabolic profile of UCP1006 and UCP1015 
show that incorporation of branching at the propargyl position increases the half-life by 
reducing the pyridyl-N-oxide rate.  Similarly, comparison of UCP1015 and UCP1021 
suggests that the placement of a 2’ methoxy substituent increases metabolic half-life, 
although the relative metabolite distribution is largely unaffected.  Taken together, 
substitution near the acetylenic linker, at either the propargylic or the C2’ position, 
slows down the metabolism at the distal pyridine nitrogen likely due to the altering the 
presentation of the pyridyl nitrogen to the cytochrome P450s active site [14].  
It was foreseen that incorporation of both of these design elements may extend the 
overall metabolic stability of lead compounds while maintaining the pharmacological 
potency.  A hybrid compound, UCP1040, was predicted to fit into the binding pocket of 
DHFR.  A model of UCP1040 bound to S. aureus DHFR suggested conservation of the 
hydrogen bonds between the pyrimidine and active site residues as well as hydrophobic 
interactions between the C6 ethyl and propargyl group with surrounding residues Val 31, 
Leu28, Leu54, Ile51, and Phe92. The 2’ methoxy group may form positive van der Waals 
interactions with Met42 or Thr46.  Thus, UCP1040 was synthesized and tested [18].   
Table 2. Predicted mass, diagnostic ions and assignment of metabolites for compounds 
3, 8 and 10 (UCP1006, UCP1021 and UCP1040). 
Compound 
Identifier 
Predicted M+H Diagnostic Daughter 
Ions 
Notes 
3 374.1976 175.1; 212.1; Parent 
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M3-1b 390.1925 373.1888; Pyridine-N-oxide a 
M3-2 360.1819 175.1; 198.1; Demethylation 
M3-3b 390.1925 213.1141; 372.1836; Alternative oxidation on the 
pyrimidinyl substructure 
M3-4b 390.1925 373.1914; Pyrimidinyl N-oxide a 
8 360.1819 175.1; 198.1; Parent 
M8-1 376.1768 175.1; 214.1; Pyridine-N-oxide a 
M8-2 346.1663 175.1; 184.1; Demethylation 
M8-3 376.1768 198.1; Alternative oxidation on the 
pyrimidinyl substructure 
10b 374.1976 175.1008; 197.0862; Parent 
M10-1b 390.1925 175.0974; 228.1016; 
373.1907 
Pyridine-N-oxide a 
M10-2b 360.1819 175.1021; 184.0792; Demethylation 
M10-3b 390.1925 174.0863; 228.1010; 
372.1768; 
Alternative oxidation on the 
pyrimidinyl substructure 
M10-4b 390.1925 175.0955; 228.1010; 
373.1862; 
Pyridine-N-oxide a 
M10-5b 390.1925 212.1076; 372.1859 Alternative oxidation on the 
pyrimidinyl substructure 
a Structure confirmed by synthesized standards. 
b Analyte masses were accurate to 10ppm.  
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A metabolic stability study of UCP1040 with similar testing conditions showed 
significantly improvement with doubled half-life (t1/2 = 65 min) relative to the initial lead 
series.  LC-MS/MS analysis of the microsomal mixture revealed five major metabolites 
(Fig. 5; Table 2). M10-2 (20.3%) was again easily assigned as the O-demethylation 
product.  The other four products (M10-1, M10-3, M10-4 and M10-5) show 16 mass unit 
increases compared the parent compounds, indicating mono-oxidation.  With similar 
fragmentation pattern, the 2’-methoxy donor promoted dissociation together with the 
propargylic linker, generating diagnostic daughter ions to assign pyrimidinyl and 4-
phenylpyridinyl oxidation.  Synthetic pyridinyl and pyrimidinyl N-oxidation products 
were also used for metabolite verification.  Semi-quantitative analysis of metabolite 
distribution revealed that the pyridine-N-oxide remained the predominant metabolite 
(M10-1), accounting for 54.3% of the total metabolite.  Another chemically matched 
product pyrimidine-N-oxide (M10-4) was present at 7.2%.  The CID spectrum of the 
remaining two identified mono-oxidation products (M10-3 and M10-5) suggested 
oxidation on the pyrimidinyl moiety and were tentatively assigned to the C6 position of 
the pyrimidine.   
Insight from the crystal structure of UCP1006 bound to wild type S. aureus DHFR 
[24]clearly shows that the pyridyl nitrogen is solvent exposed and does not directly 
interact with the enzyme, suggesting that its major metabolite pyridine-N-oxide may 
retain the enzymatic inhibition activity.  Chemically synthesized pyridine-N-oxide of 
UCP1040 (M10-1) was purified by HPLC and the weight was determined using a 
UCP1040 standard curve generated by LC-MS (assuming the same ionization efficiency).  
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The residual activity of M10-1 was evaluated with a  Candida glabrata DHFR inhibition 
assay [15].  Excitingly, M10-1 shows promising C. glabrata DHFR inhibition (IC50 = 45 nM), 
indicating the formation of an active metabolite.  
 
 
Figure 5. Major metabolites derived from compounds 2, 3, 7, 8, and 10 (UCP1005, 
UCP1006, UCP1015, UCP1021 and UCP1040). 
 
 
4.4. Conclusions 
The metabolite identification study of lead pyridine serial propargyl-linked antifolates 
revealed that the major metabolic routes are pyridine-N-oxidation and demethylation 
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on the phenyl methoxy group.  SPR analysis suggested that the propargylic methyl and 2’ 
methoxy at adjacent phenyl substitutions increased metabolic stability.  A hybrid 
compound UCP1040 was therefore synthesized and exhibited marked half-life 
improvement.  The increase in metabolic stability likely resulted from the lower N-
oxidation rate at the distal pyridine position.  The major UCP1040 metabolite also shows 
potent antifungal activity.  To further understand potential ADME weaknesses and 
improve the drug likeliness of propargyl-linked antifolates, additional strategies to 
optimize water solubility and metabolic stability will be investigated.   
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Chapter 5 
Solubility and metabolic stability optimization  
5.1. Introduction 
Lead propargyl-linked antifolates have been proven to be potent inhibitors against 
Staphylococcus aureus and Candida spp [1-4].  However, potent ligands are not 
necessarily efficacious drug molecules.  To further precede these drug discovery efforts, 
lead compounds with optimal drug like properties, which will translate to good drug 
exposure in vivo need to be developed. 
Initial ADME assessment of lead propargyl-linked antifolates revealed poor water 
solubility and metabolic stability.  Preliminary efforts to modify biphenyl series 
compounds by introducing heterocyclic functional groups reduced hydrophobicity, 
balanced overall molecule polarity and increased water solubility [5].  In addition, early 
metabolic stability evaluation and metabolite identification studies also provided helpful 
strategies to prolong in vitro microsomal half-live.  To effectively deliver high doses of 
drug and achieve good drug exposure in vivo, improved lead compounds with less 
metabolic “soft spots” and better water solubility are warranted.  
In this chapter, a strategy to incorporate crystallographic insight and improve water 
solubility by substituting more hydrophobic groups with polar functionality while 
maintaining antimicrobial potency will be implemented.  Detailed SPR analysis will also 
be performed to increase metabolic stability by blocking the key metabolic oxidation 
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sites.  New lead compounds with better ADME properties will be designed, synthesized 
and evaluated.  
5.2. Optimizing the water solubility of propargyl-linked antifolates 
The evolution of propargyl-linked antifolates has led to a significant increase in 
hydrophobicity.  As described in chapter 3, preliminary assessment indicates that 
biphenyl series lead compounds precipitate from DMSO and biological buffers over time.  
Initial attempt to improve water solubility of biphenyl lead compounds by introducing 
heterocyclic functionality effectively reduced cLogD7.4 values and increased 
experimental solution solubility with the presence of HPMC.  To further increase the 
polarity of the lead compounds and select better drug-like antifolates for animal based 
efficacy testing, multiple modification approaches were attempted.  
5.2.1 Substitution of the adjacent aromatic ring  
The search for effective dual inhibitors against C. glabrata and C. albicans has lead to 
the discovery of para- linked compounds (distal aromatic ring on the para position of the 
adjacent aromatic ring, e.g. UCP111H and UCP111E, Fig. 1.), that exhibited excellent 
potency in both enzymatic and fungal growth inhibition [4, 6].  Similar to their meta-
linked analogues (UCP111D, UCP111D4M etc), these para-linked biphenyl lead 
compounds are also associated with poor water solubility.  To improve water solubility, 
substituting the distal phenyl ring (UCP1043) with more polar pyridine functionality 
(UCP1044) significantly decreased the calculated LogD value at pH7.4 from 4.66 to 3.44. 
UCP1044 is potent against DHFR from C. grabrata and C. albicans, with IC50 values at 
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19nM and 33nM, (Fig 1.) respectively.  However, despite UCP1044 being a potent C. 
grabrata inhibitor (MIC=0.78 µg/mL), it doesn’t effectively inhibit C. albicans growth 
(MIC=25 µg/mL) [6].  The loss of antifungal activity is likely due to the poor membrane 
permeability through C. albicans outer membrane [7].  
 
 
Figure 1. Enzymatic inhibition and antifungal activity of para-linked inhibitors. 
 
Comparisons of the activity of UCP1043 and UCP1057 (Fig 1.) indicate that the methoxy 
substitution is well tolerated at the 2’ position of the adjacent phenyl ring but not 
required for potency.  Therefore, adding a polar basic nitrogen to the adjacent ring may 
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increase the water solubility and balance the overall polarity of the molecule, without 
losing the dual antifungal potency.  In contrast to distal pyridines, incorporating pyridine 
at the adjacent position (UCP1051) did not significant increase water solubility, 
comparing to UCP111H (Fig 2), 25 µg/mL versus 20 µg/mL.  However, UCP1055 featuring 
a much more polar pyrimidine substitution at the adjacent position exhibited a sharp 
improvement to 60 µg/mL.  More excitingly, UCP1055 also show potent antifungal 
activity with MIC value of 0.78 µg/mL and 0.19 µg/mL against C. glabrata and C. albicans, 
respectively.  
 
 
Figure 2. Structure and solubility of para-linked lead compounds. 
 
5.2.2 Double pyridine analogues  
To prove in vivo efficiency against MRSA or fungal infection, good drug exposure is 
desired.  To ensure high dosage delivery, further improvement in water solubility is 
needed.  Previous approaches to modify hydrophobic phenyl rings to polar heterocyclic 
functional group significant decreased cLogD values at pH7.4 and increased water 
solubility.  It is reasonable to assume that changing both phenyl rings to nitrogen-
containing pyridine will further increase solubility.  In silico calculation also supported 
that with double pyridines, cLogD values at pH7.4 of analogues UCP1093 and UCP1094 
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(Fig 3.) decreased to 2.77 and 2.38, respectively.  Crystallographic insight also suggested 
that both of the compounds should fit in the SaDHFR binding site with similar or 
improved affinity (data not shown).  However, surprisingly, UCP1094 was not soluble 
even at 1 mg/mL in DMSO, which inhibited efficient solubility testing.  UCP1093 was 
soluble at 20 mg/mL in DMSO stock, but lost its antibacterial activity with MIC values of 
2.5 µg/mL (over 30 folds less potent than UCP1006) against wild type S. aureus.  
Noticeably, UCP1094 DMSO stock at 20 mg/mL was turbid at room temperature; 
however, it solubilized when heated with a flame for a few seconds.  This temperature 
driven phenomenon likely indicated that the low solubility of UCP1094 was because of 
crystallization within the aqueous solution instead of low solubility.  Taken together, 
future solubility optimization should focus on preventing the stacking or crystallization 
effect instead of reducing hydrophobicity alone. 
 
Figure 3. Structure and cLogD7.4 value of double pyridine analogues 
 
5.3. Optimizing the metabolic stability of propargyl-linked antifolates 
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Initial assessment (chapter 4) suggested that the metabolic stability of lead pyridine 
series antifolates are sensitive to the substitutions around the propargylic position and 
the 2’ or 3’ position of the adjacent phenyl ring.  The hybrid compound UCP1040 with 
propargyl methyl and 2’ methoxy shows improved metabolic half-life in vitro with 
mouse liver microsomes (MLM).  Metabolite identification study indicated that despite 
the metabolic half-life difference between UCP1006 (35 mins) and UCP1040 (65 mins), 
two compounds share similar metabolic routes.  To further improve in vitro metabolic 
stability and potentially improve in vivo drug exposure, several strategies were 
implemented in this section.  
5.3.1 Improving metabolic stability with dioxolane 
Metabolic stability and metabolite identification study of UCP1006 and UCP1040 
indicated that introduction of 2’ methoxy group significantly increased the metabolic 
half-life by reducing the N-oxidation rate on the distal pyridine.  The remotely controlled 
effect of the positioning of the methoxy is likely due to a change in the conformation of 
the minimal energy form (data not shown).  A 3’ 4’ dioxolane on the adjacent phenyl 
ring is hypothesized to have a similar effect with low N-oxidation rate on the distal 
pyridine.  At the same time, the dioxolane should further prolong the metabolic half-life 
by blocking the demethylation, which is the second predominant metabolic route for 
both UCP1006 and UCP1040.  Furthermore, structural evaluation using crystal structure 
of wild type SaDHFR bound to UCP1006 indicated that the binding pocket of SaDHFR is 
large enough to accommodate the 5 member ring (data not shown).  With the 
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hypothesis that the dioxolane analogue will retain antibacterial activity while improving 
metabolic stability, UCP1038 was then synthesized and evaluated.  
 
Figure 4. Structure, metabolic stability, and antibacterial activity of dioxolane analogues 
 
UCP1038 exhibited excellent antibacterial potency with an IC50 value of 17 nM against 
SaDHFR and a MIC value of 0.078 µg/mL.  In addition, the metabolic stability of UCP1038 
significantly improved with a half-life of 79mins in MLM and over 270mins in human 
liver microsomes (HLM).  To understand the mechanism of the enhancement of 
metabolic stability and the metabolic routes of UCP1038, a metabolite identification 
study was performed with MLM by LC-MS/MS in a similar testing condition as described 
before.  Surprisingly, despite the observation of parent compound loss during the 
incubation, no obvious metabolite was detected.  It was speculated that UCP1038 might 
have covalently bound to cytochrome P450s (CYP) during the incubation with MLM and 
therefore acted as a suicide inhibitor.  Literature suggested that 1, 3-Benzodioxoles 
analogues commonly act as quasi-irreversible CYP450 inhibitors, the mechanism of 
which is described in Figure 5 [8-9].  As shown, bioactivation of 1, 3-benzodioxole 
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derivatives are initiated via hydrogen atom abstraction from the methylene carbon or 
by elimination of water from a hydroxymethylene intermediate, generating a reactive 
carbene intermediate, which subsequently forms a metabolite-intermediate (MI) 
complex with ferrous iron from the CYP450s.  The hydroxymethylene intermediate can 
also undergo demethylenation, yielding a catechol intermediate, which may covalently 
bind to the CYP apoprotein.  To further validate this hypothesis, a glutathione (GSH) 
trapping assay with MLM was pursued as reported [10].  However, no GSH-adduct was 
detected by tandem MS.  In addition, the metabolic stability was unchanged with the 
presence of GSH.  
 
Figure 5. Mechanism-based CYP inhibition and formation of MI complex by 1, 3-
Benzodioxoles[8] 
 
A well-accepted strategy to reduce potential reactive intermediate formation is to 
replace the dioxolane hydrogens with deuterium [11-13].  Thus, UCP1070, a deuterium 
substituted analogue of UCP1038 was synthesized.  UCP1070 retained potent 
antibacterial activity with a MIC value of 0.078 µg/mL and superb metabolic stability 
with T1/2 of 91 min with MLM and 102 min with HLM.  A metabolite identification study 
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of UCP1070 with MLM shows only one major phase I metabolite with m/z at 376 (-14 
mass unit comparing to protonated parent compound).  The CID spectrum of the 
metabolite indicated a loss of 14 mass units on the benzodioxolane-pyridinyl moiety of 
the molecule.  The metabolite structure (P1 metabolite) was tentatively assigned as loss 
of the methylene group (shown in Fig 6).  Metabolic incubation with mouse liver S9 
fractions in the presence of both phase I and II cofactors for UCP1070 also suggested 
that the phase I metabolite can also undergo phase II glucuronidation.  The 
glucuronidation product was tentatively assigned as O-glucuronide conjugation on the 3’ 
or 4’ position of the phenyl hydroxyl (shown in Fig 6). 
 
Figure 6. Structure and m/z values of UCP1070 and proposed metabolites 
 
UCP1070 exhibited potent antibacterial activity and exceptional metabolic stability in 
vitro.  Different from UCP1038, the deuterium substitution likely reduced the formation 
of the reactive metabolite, which may translate into decreased covalent binding burden 
in vivo.  Overall, UCP1070 is a promising lead compound that should be further 
characterized for other in vitro ADME properties and evaluated for in vivo 
pharmacokinetics and efficacy.  
5.3.2 Improving metabolic stability with single enantiomers  
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Initial testing for lead propargyl-linked antifolates indicated that the propargylic methyl 
substitution is important to retain metabolic stability.  The crystal structure of UCP1006 
bound to wild type SaDHFR also suggested that only one of the racemic molecules is 
present.  To explore the stereo chemistry of the propargyl position and its relationship 
to antibacterial activity, three pairs of single enantiomers UCP1006 (UCP1061 and 
UCP1062), UCP1040 (UCP1063 and UCP1064), and UCP1038 (UCP1098 and UCP1099) 
were synthesized and evaluated (Fig 7.).   
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Figure 7. Structure, antibacterial activity and metabolic half-life of UCP1006, UCP1040, 
UCP1038 and its single enantiomers. 
 
Strikingly, UCP1063, the R-enantiomer of UCP1040 was 16 fold more potent than its 
racemic mixture with a MIC value of 0.0195 µg/mL against S. aureus (compared to MIC 
value of 0.625 µg/mL for racemic mixture).  UCP1064, the S-enantiomer of UCP1040 also 
exhibited improved antibacterial activity with MIC value of 0.3125 µg/mL.  Comparing to 
the racemic mixture, UCP1063 also showed improvement in metabolic stability with a 
half-life of 97 minutes and 146 minutes with MLM and HLM, respectively.  UCP1064 
exhibited a similar metabolic half-life with MLM (61 min) compared to UCP1040.  A 
metabolite identification study with UCP1063 and UCP1064 with MLM indicated that 
UCP1064 generates one more metabolite with retention time at 8.74 min compared to 
UCP1063, which may explain the difference in metabolic half-life.  Combining the CID 
spectrum of UCP1064 and UCP1040 metabolites, it appeared that the unique metabolite 
for UCP1064 was the hydroxylation product on the pyrimidyl moiety of the molecule 
(shown as Fig 8). 
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Figure 8. Upper panel chromatogram of UCP1064 after 2hr MLM incubation at m/z=390; 
lower panel chromatogram of UCP1063 after 2hr MLM incubation at m/z=390; 
 
Similar to UCP1040 and its single enantiomers, the other two pairs of compounds 
exhibited differences in antibacterial activities.  The S-enantiomer of UCP1006 (UCP1063) 
and the R-enantiomer of UCP1038 (UCP1099) both were 16 fold more potent than the 
other enantiomers.  It was hypothesized that the two enantiomers may antoginize each 
other, resulting in a lower potency of the racemic compounds.  However, detailed 
mechanism of this is still under investigation.  
5.3.3 Improving metabolic stability with a modified pyridine ring  
Previous metabolite identification studies revealed that the predominant route of 
metabolism for lead propargyl-linked antifolates is N-oxidation on the distal pyridine 
ring.  To block the reaction, several analogues with modified distal functionality were 
synthesized and tested.  UCP1066 is characterized by a distal pyrazine group with two 
basic nitrogen atoms.  It was proposed that the second nitrogen would balance the 
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electron density of the aromatic ring and result in decreased binding to CYP450 
metabolism and prolonged half-life.  UCP1071 featured a 2’-pyridine, instead of a 4’-
pyridine in UCP1040.  The rotation of the pyridine ring aimed to reduce the accessibility 
of basic nitrogen to CYPs and therefore reduce the N-oxidation.  UCP1076 and UCP1077 
highlighted protected 4’-pyridine distal substitution. The addition of hydrophobic 
functionality next to the pyridine nitrogen should limit the binding to CYP, shield the 
pyridine nitrogen and block the pyridine N-oxide formation.  
 
Figure 9. Structure and in vitro MLM metabolic half-life of UCP1066, UCP1071, UCP1076 
and UCP1077.  
 
53 
 
Surprisingly, none of the four newer compounds show improved metabolic stability 
compared to UCP1040.  The metabolite identification study of UCP1076 with MLM 
indicated that the dimethyl pyridine completely eliminated N-oxidation formation 
observed with in exposed pyridine (UCP1006 and UCP1040).  The only major phase I 
metabolite detected after MLM incubation was a demethylation product; only a trace 
amount of mono-hydroxylation product was detected.  When incubated in the presence 
of both phase I and phase II cofactors uridine diphosphate glucuronic acid (UDT-GA), 
acetyl-CoA and 3'-phosphoadenosine-5'-phosphosulfate (PAPS), the phase I 
demethylation metabolite likely underwent phase II conjugations, generating two 
additional metabolites with m/z=564.2 and 404.2.  The metabolites structures were 
tentatively assigned as shown in figure 10.  However, despite the elimination of the 
predominant metabolic route, the overall metabolic half-life with MLM did not improve 
(t1/2=35 mins) compared to UCP1040 (t1/2=65 mins).  Therefore, more quantitative 
evaluation for metabolite formation is needed in the future. 
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Figure 10. Structure and m/z values of UCP1076 and proposed metabolites 
 
5.4. Conclusions 
To improve the water solubility of the lead propargyl-linked compounds while 
maintaining potent antimicrobial activity, several approaches to introduce more polar 
functional groups were explored.  However, the decrease in lipophilicity did not 
effectively translate into increased water solubility, indicating that the low water 
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solubility of several lead compounds likely results from crystallization in solution instead 
of high hydrophobicity.  Metabolic stability optimization efforts were also implemented.  
Analogues with deuterated benzodioxoles at the adjacent position and single 
enantiomers at the propargylic position exhibited potent antibacterial activity and 
promising metabolic stability.  Additional substitutions at the distal ring position were 
also investigated.  Although less stable with MLM, dimethypyridine analogue UCP1076 
completely blocked the pyridine-N-oxidation formation in microsomes.  To better 
support the development of propargyl-linked antifolates and rank order metabolically 
stable lead compounds, quantitative analysis of multiple time-point microsomal stability 
testing at low testing concentration will be performed.  CYP inhibition of lead 
compounds will be also evaluated to assess the potential to induce drug-drug 
interactions.  Candidate compounds with exceptional in vitro antimicrobial activity and 
excellent ADME properties will be selected for in vivo PK and efficacy evaluation. 
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Chapter 6 
In vivo efficacy and pharmacokinetics evaluation 
6.1. Introduction 
UCP1006 is a third generation propargyl-linked antifolates that potently inhibits the 
dihydrofolate reductase (DHFR) enzymes from S. aureus (SaDHFR) and C. glabrata 
(CgDHFR) and inhibits the growth of these species in vitro [1-2].  To evaluate the in vivo 
effectiveness of UCP1006, an established murine model of S. aureus bacteremia caused 
by a community-acquired MRSA isolate and an established murine model of invasive 
candidiasis caused by C. glabrata were used through collaboration with Dr. Nathan 
Wiederhold’s research group in The University of Texas Health Science Center at San 
Antonio (UTHSCSA).  Initial dose tolerability/pharmacokinetic experiments in which 
UCP1006 is administered by intraperitoneal injection were conducted.  The in vivo 
antibacterial activity of UCP1006 was compared to vancomycin and the in vivo 
antifungal efficacy of UCP1006 was compared to fluconazole and caspofungin.   
6.2. Evaluate UCP1006 as treatment for MRSA bacteremia 
6.2.1 S. aureus isolate preparation and murine bacteremia model 
LAC300, a USA300 community-acquired MRSA strain, was used in this study.  This is a 
well-characterized clinical isolate that is known to cause lethal, disseminated disease 
when inoculated intravenously [3-4].  BALB/c mice were inoculated via the lateral tail 
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vein in order to establish S. aureus bacteremia.  Each animal was challenged with ~6 x 
107 bacterial cells in the survival arm and ~1 x 107 cells in the tissue burden arm.  These 
two different inocula sizes were used as the higher inoculum results in a rapid but 
consistently lethal infection, while the lower inoculum allows for the comparison of 
tissue burden reductions among different groups at a predetermined time point. 
Following inoculation, mice were monitored until day 21 to assess survival.   
6.2.2 Preparation of UCP1006 HCl salt 
UCP1006 was prepared by dissolving the monohydrochloride salt powder in DMSO to 
concentrations of 25, 50 and 100 mg/mL.  The DMSO stocks were diluted 50-fold into a 
sodium acetate buffer that is isotonic with 157 mM Na+ and 16 mM acetate containing 
0.1% hydroxypropylmethylcellulose (HPMC) (157 mM Na+ = 141 mM NaCl and 16 mM 
NaAcetate) to final concentrations of 2, 1 and 0.5 mg/mL, and the final concentration of 
DMSO was 2%.  These concentrations (0.5, 1, and 2 mg/mL) correspond to dosages of 4, 
8, and 16 mg/kg.  The DMSO stocks of UCP1006 were frozen and shipped on dry ice to 
UTHSCSA along with the sodium acetate buffer.  For each day of dosing UTHSCSA was 
freshly prepare the dilutions of UCP1006 in the sodium acetate buffer to the 
concentrations listed above.  In the infection model, the commercially available 
intravenous preparation of vancomycin was used and prepared according to the 
package insert. 
6.2.3 Antibacterial activity testing strategy 
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UCP1006 as monotherapy for S. aureus bacteremia was evaluated with vancomycin 
serveing as the positive control.  This vancomycin treatment regimen has been shown to 
improve survival in the murine model of staphylococcal bacteremia and mimic the 
pharmacokinetics (AUC and Cmax) achieved with the commonly used dose of 1 g every 
12 hours in humans, respectively [5]. Treatment was administered 4 hours post 
intravenous challenge, and mice were randomized into one of five treatment groups as 
described below and listed in Table 1: 
1) Placebo controls – 0.1% HPMC IP injection twice daily 
2) UCP1006 4 mg/kg by IP injection twice daily 
3) UCP1006 8 mg/kg by IP injection twice daily 
4) UCP1006 16 mg/kg by IP injection twice daily 
5) Vancomycin 110 mg/kg by SC injection twice daily 
Survival and tissue burden arms were included.  In the survival arm, antibacterial 
therapy was continued through day 6 post-inoculation.  Mice were then monitored off 
therapy at least twice daily to prevent and minimize unnecessary pain or distress until 
day 21 post-inoculation.  Moribund animals were identified by the criteria listed above, 
and any animal demonstrating > 1 of these will be humanely euthanized. 
In the tissue burden arm, treatment was continued for four days.  One day post-
treatment, mice were humanely euthanized, and the target organs (e.g., kidneys, liver, 
and brains) were harvested, weighed, and homogenized in sterile saline.  Ten-fold serial 
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dilutions of the homogenates were prepared in sterile saline and plated onto TSA plates.  
The plates were incubated at 37°C for 24 hours, and the CFU/g of each tissue was 
determined.  In addition, organs were also collected from mice as they succumb to 
infection and in those that survive to day 21 and tissue burden were measured as 
described above. 
Table 1. Number of mice per group for the survival and tissue burden arms. 
Group Survival Arm Tissue Burden Arm 
Placebo Controls 10 10 
 
UCP1006 4 mg/kg IP BID 10 10 
 
UCP1006 8 mg/kg IP BID 
 
10 10 
UCP1006 16 mg/kg IP BID 
 
10 10 
Vancomycin 110 mg/kg SC BID 
 
10 10 
Total Animals 
 
50 50 
 
6.2.4 Pharmacokinetics analysis of UCP1006 after pre-exposure 
To evaluate the tolerability/pharmacokinetics of UCP1006, a preliminary experiment 
was conducted using uninfected mice.  Unlikely traditional pharmacokinetics evaluation, 
due to the limit availability of drug, a PK assessment using a tolerability experiment 
setup with 5 days pre-drug exposure was performed.  There were 18 animals in each 
dosage group.  Mice were administered UCP1006 at doses of 4, 8, or 16 mg/kg twice 
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daily IP injection for 5 days same as the tissue burden assay.  At specific time points 
following the last dose (0.5, 1, 2, 4, 8 and 12 hours), blood and kidneys were collected 
from 3 mice per time point in each group.  The blood was collected into EDTA tubes by 
cardiac puncture, and within 15 minutes, the blood samples were centrifuged (3000 g x 
5 minutes) and the plasma separated and frozen.  Plasma and kidney samples were 
maintained at -80°C and shipped frozen to the University of Connecticut.  UCP1006 
concentration in mice plasma samples was determined by LC-MS.  Pharmacokinetics 
parameters of UCP1006 were estimated by compartmental analysis using the program 
WINNONLIN.  
Figure 1. Profile of plasma concentration versus time of UCP1006 in mice  
 
UCP1006 was well tolerated at all testing dosages and no significant adverse effects 
were observed.  The pharmacokinetic parameters of UCP1006 following IP injections 
after 7days bi-daily exposure at 4mg/kg, 8mg/kg and 16mg/kg in mice are summarized 
in figure 1 and table 2.  Overall, UCP1006 underwent fast clearance in mice.  Whole 
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body clearance of UCP1006 also exhibited a dose dependant pattern, with CL value 
254.91 mL/min/kg, 89.36 mL/min/kg and 39.4 mL/min/kg at 4, 8 and 16 mg/kg dosages, 
respectively.  The dose dependent difference in drug intrinsic clearance might result 
from potent CYP inhibition (discussed in later chapters).  The intrinsic half-life of 
UCP1006 is short and is similar despite different dosages (0.32~0.5hr).  A separated PK 
study using UCP1006 without drug pre-exposure at 2 mg/kg using IV administration 
suggested similar (comparing 4 mg/kg IP with 7 days drug exposure) intrinsic half-life 
(0.41hour). However, slower clearance was observed (32.3 mL/min/kg).  Therefore, a 
significant CYP induction or non-CYP mediated drug clearance may play an important 
role.   
Due to the unexpected fast clearance and relative long sampling interval, a plasma 
concentration error was observed.  The estimated Cmax of UCP1006 at 16 mg/kg is 
14.78 µg/mL, about 190 fold higher than the in vitro MIC value against S. aureus.  
Therefore, even with relative low drug exposure, UCP1006 is still selected for later in 
vivo efficacy testing in MRSA infection murine model.  
Table 2. Pharmacokinetics of UCP1006 in mice at 4, 8 and 16mg/kg 
Dosage 4mg/kg 8mg/kg 16mg/kg 
Half-life 
(hr) 
 
0.50 
 
0.34 
 
0.32 
AUCa 
(hr*µg/mL) 
 
0.26 
 
1.49 
 
6.77 
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Cmaxb 
(µg/mL) 
 
0.37 
 
3.03 
 
14.78 
Clearance 
(mL/min/kg) 
 
254.91 
 
89.36 
 
39.40 
Vssc 
(L/kg) 
 
10.84 
 
2.64 
 
1.08 
a Area under curve 
b Estimated max concentration  
c Steady state volume of distribution  
 
6.2.5 In vivo antibacterial activity evaluation of UCP1006 
UCP1006 was evaluated in MSRA infected mouse model as described above.  However, 
the testing compound did not effectively clear the bacterial infection at any dosage 
tested.  None of the animals in either survival or tissue burden arm survived.  Possible 
reasons for UCP1006 this lack of potent antibacterial activity in vivo are low drug 
exposure due to the fast intrinsic clearance or the high level of thymidine in mouse.  The 
plasma thymidine concentration in mice is around 1µM, over 10 times higher than 
human [6].  High levels of thymidine can be converted to TMP via thymidine kinase, 
therefore, bypassing DHFR inhibition blockade of folate biosynthesis pathway in mice [7].  
6.3. Evaluate UCP1006 as treatment for candidiasis 
Similar to antibacterial activity testing, antifungal potency of UCP1006 was assessed 
using a developed murine model of invasive candidiasis caused by C. glabrata in 
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collaboration with Dr. Wiederhold at UTHSCSA.  With improved formulation, a higher 
administration dosage was achieved at 16, 32 and 48 mg/kg.  A preliminary PK and 
tolerability experiment was conducted with uninfected immunosuppressed mice.  The 
testing strategy and animal numbers were similar as described above.  Previous study 
indicated that UCP1006 has a short intrinsic half-life in mouse.  Therefore, short initial 
sampling time points were selected to achieve better PK estimation accuracy.  Blood 
samples were collected at 0.17, 0.5, 1, 2, 4 and 12 hours after the last dose and plasma 
samples were isolated for drug quantification.   
UCP1006 was well tolerated at  the 16 mg/kg in the new formulation.  However, mild to 
moderate toxicity (ruffled fur and altered locomotion after dosing) was observed at 32 
and 48 mg/kg.  One animal in the 48mg/kg group died during the tolerability testing.  At 
32mg/kg, UCP1006 posed a similar intrinsic clearance value (50.06mL/min/kg) as 
observed before in 16mg/kg dosage group, with 0.38 hr half-life and steady state 
volume of distribution (Vss) 1.78 L/kg.  The calculated AUC and Cmax both increased to 
9.68 hr* µg/mL and 17.84 µg/mL, respectively.  However, at 48mg/kg, the PK profile did 
not fit in the one compartment IV bolus model as before. Significant drug accumulation 
was observed up to 4hours after dosing.  
UCP1006 at 32mg/kg was selected for in vivo efficacy evaluation.  The efficacy was 
determined by a kidney fungal burden assay similar to the tissue burden arm testing as 
described above.  However, no statistical significance was achieved when the treatment 
and control groups were compared, suggesting UCP1006 failed to clear the C. glabrata 
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infection.  Possible reasons are similar as described before due to the low drug exposure 
and high thymidine level in mouse.  To better assess the in vivo efficacy of propargyl-
linked compounds, better drug exposure and eliminated high thymidine salvage effects 
are both critical.  
6.4. Evaluate the tolerability and PK profile of UCP1063  
With extended in vitro microsomal metabolic stability (t1/2=135mins with MLM) and 
improved antibacterial potency (MIC=0.02µg/ml agasint MRSA), UCP1063 was expected 
to have better drug exposure and selected as a new investigational agent for in vivo 
efficacy testing.  A similar testing approach using the LAC300 MRSA strain generating 
bacteremia in murine model was conducted.  A pilot PK and tolerability testing was also 
included for investigating the novel delivery formulation and high dosage (up to 
128mg/kg).  Instead of using IP injection, oral gavage administration was used to 
achieve highest possible dosages at 16, 64 and 128 mg/kg (18, 5 and 5 animals each).  
Another group of 18 mice using IP injection at 16 mg/kg was also included for 
bioavailability determination.  
UCP1063 was well tolerated at 16 mg/kg.  At 64 mg/kg, all five animals survived the 7 
days treatment. However, significant weight loss was observed for the animals, 
suggesting the dosage cannot be used for efficacy testing.  At 128 mg/kg, one mouse 
died after two doses and the other four animals experienced severe adverse effects and 
had to be euthanized shortly after the third dose.  
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 Table 3. Pharmacokinetics of UCP1063 in mice at 16 mg/kg through IP and PO 
administration 
Administration IP PO 
Half-life 
(hr) 
 
0.33 
 
0.19 
AUC 
(hr*µg/mL) 
 
4.90 
 
0.41 
Cmax 
(µg/mL) 
 
10.16 
 
1.44 
Clearance 
(mL/min/kg) 
 
54.37 
 
658.42 
Vss 
(L/kg) 
 
1.57 
 
11.10 
 
The pharmacokinetic parameters of UCP1063 at 16mg/kg through IP and PO 
administration are summarized in Table 3.  Although UCP1063 exhibited higher 
metabolic stability than UCP1006 in vitro, the two compounds have similar intrinsic half-
lives in the mouse (around 0.3 hour at 16mg/kg IP).  This suggests that the improvement 
of in vitro metabolic stability with microsomes is an artifact and may be due to CYP 
inhibition at relatively high concentrations.  The bioavailability of UCP1063 is 8.3 %, 
significantly lower than UCP1006 (82.5 % in rats).  Due to unexpected short metabolic 
half-life, initial sampling time points were long. The first sampling time was determined 
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at 30 minutes after last dosage. With calculated intrinsic half-life shorter than 20 
minutes, data collected for the oral administration group did not detect the initial phase 
of drug exposure and therefore, may have poor estimation.  Even with potent 
antibacterial activity in vitro, UCP1063 showed similar drug exposure at 16mg/kg as 
UCP1006.  At higher testing dosage (64 and 128mg/kg), UCP1063 was not tolerated in 
animals, which suggested no increased drug exposure can be achieved through high 
dosage administration.  Therefore, additional efficacy study in MRSA infected murine 
model for UCP1063 was not pursued at this moment.    
6.5. Conclusions 
To evaluate the in vivo efficacy of UCP1006 against bacteremia and candidiasis caused 
by MRSA and C. glabrata, murine infectious models were used with the collaboration 
with Dr. Wiederhold’s group in UTHSCSA.  UCP1006 exhibited good tolerability at 
32mg/kg and lower dosages.  PK evaluation after 7 days bi-daily IP administration 
suggested that UCP1006 was quickly cleared in mouse with an intrinsic half-life of 0.3 
hours.  Due to the low drug exposure and high level thymidine level in murine animals, 
UCP1006 did not effectively eliminate bacteremia and candidiasis in infected animals.  
However, an independent study using similar murine infection model with thymidine 
kinase knockout MRSA strain showed efficacy of UCP1021 with an ED50 value around 
4mg/kg (data not shown).   
UCP1063 exhibited better metabolic stability and enhanced antibacterial activity 
compard to UCP1006 in vitro.  Nevertheless, no significant drug exposure improvement 
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was observed in vivo.  In addition, UCP1063 was less orally bioavailable and less 
tolerated.  Therefore, additional efficacy testing of UCP1063 in MRSA infected animals 
was discontinued.    
Although highly potent and tolerable propargyl-linked antifolates with excellent PK 
properties are still under development, our knowledge of improving potency and ADME 
performance is constantly improving.  The research described here has led to 
identification of compounds with good aquous solubility, in vitro metabolic stability and 
low CYP inhibition.  Next steps should incorporate more quantitative analysis of in vitro 
clearance and establish better in vitro and in vivo correlation for compound rank 
ordering and drug candidate selection.  
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Chapter 7 
CYP inhibition and in vivo drug exposure optimization 
7.1. Introduction 
Cytochrome P450 (CYP) enzymes play a critical role in xenobiotic metabolism [1].  Out of 
many different isoforms within the CYP superfamily, CYP3A4 and CYP2D6 are 
particularly important and contribute to the metabolism of about 58% of common drugs 
on the market [2].  Drugs that inhibit CYP may impact the pharmacokinetic profile of 
other drugs and can result in serious drug-drug interactions [3].  Therefore, it is 
important to monitor CYP inhibition during the drug discovery process.  During the 
initial CYP inhibition assessment, it is commonly accepted that compounds with IC50 
values higher than 10 µM against major CYP isoforms are weak CYP inhibitors; 
compounds with 3 µM <IC50< 10 µM are moderate CYP inhibitors; while compounds 
with IC50< 3 µM are strong CYP inhibitors [4].  
Previous chapters described that early lead propargyl-linked antifolates were associated 
with fast metabolic clearance.  Initial lead optimization effort significantly increased the 
metabolic stability.  However, the in vivo PK testing suggested no drug exposure 
improvement even though UCP1063 exhibited a 3 fold longer half-life when compared 
to UCP1006 in vitro.  The experimental conditions used were metabolic incubation with 
mouse or human liver microsomes with a relatively high concentration of testing 
compounds (5 µg/mL).  With potent CYP inhibition, the improved in vitro metabolic 
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stability may likely be due to the artificial effects of self inhibition to metabolic CYP 
enzymes.  In this chapter, the CYP inhibition of lead propargyl-linked compounds to two 
major CYP isoforms (CYP3A4 and CYP2D6) will be tested.  In vitro metabolic half-lives 
will be further evaluated at a lower compound testing concentration (0.5µg/mL).  
Careful structure-property relationship (SPR) analysis will lead to the identification of 
candidate compounds with better metabolic stability and lower CYP inhibitory activity 
for future in vivo testing. 
 
7.2. Evaluate CYP inhibition of lead propargyl-linked antifolates 
CYP inhibition of lead compounds was tested against CYP3A4 and CYP2D6 using a 
fluorescent based assay.  Non-fluorescent isoform specific substrate 3-[2-(N, N-diethyl-
N-methylammonium) ethyl]-7-methoxy- 4- methyl-coumarin (AMMC) was incubated 
with baculovirus insect cells (BTI-TN-5B1-4) expressed human CYP2D6 enzyme 
(SupersomesTM) generating fluorescent metabolite 3-[2-(N,N-diethylamino)ethyl-7-
hydroxy-4-methylcoumarin (AHMC) (Fig 1A.)[5].  With the presence of testing 
compounds as CYP2D6 inhibitors, the metabolism of AMMC is suppressed and will 
generate the less fluorescent metabolite AHMC.  The CYP inhibition was quantified by 
comparing a negative control (without testing compounds) in a dose dependent manner 
(Fig 1B.).  Similarly, the CYP3A4 inhibition assay was performed using SupersomesTM 
with fluorogenic substrate 7-benzyloxyquinoline (BQ) and fluorescent metabolite 7-
hydroxyquinoline (HQ)[6].  The IC50 value was calculated with standard curve generated 
with fluorescent metabolite AHMC or HQ.   
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a.  
 
b. 
 
Figure 1. a, structures of AMMC and AHMC; b, inhibition pattern in the incubation 
medium including recombinant CYP2D6 supersomes with TC (test compound) as 
inhibitor.  
 
Table 1 lists the CYP3A4 and CYP2D6 IC50 values and in vitro microsomal metabolic half-
life values with MLM and HLM of lead propargyly-linked antifolates at 5µg/mL.  Most of 
these compounds (23 compounds total) are potent CYP inhibitors against CYP3A4 with 
IC50 values ranging from <0.01 µM to 0.56 µM (excluding UCP1031, UCP1055, UCP1076 
and UCP1077) and moderate CYP2D6 inhibitors with IC50 values ranging from 1.41 µM 
to >29 µM (excluding UCP1038, UCP1070 and UCP1075).  Noticeably, UCP1038 
exhibited potent CYP inhibition against both CYP3A4 (100% inhibition at 0.02 µM) and 
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CYP2D6 (IC50=0.07 µM).  This is likely related to a potential for covalent binding to the 
heme group from CYP after bioactivation [7].  UCP1070, the deuterium substituted 
analogue, was designed to slow down bioactivation of the C-H bond at the dioxolane 
and ideally should reduce the CYP inhibition potential.  Despite the fact that UCP1070 
significantly reduced the CYP3A4 inhibition (IC50=0.04 µM), it is a more potent CYP2D6 
inhibitor (IC50=0.01 µM) than UCP1038.  
Table 1. Structure, CYP inhibition and in vitro microsomal metabolic half-life of lead 
propargyl-linked DHFR inhibitors.  
Cmpd# Structure CYP3A4 
 IC50 (µM)  
CYP2D6 
 IC50 (µM) 
t1/2 MLM 
 (min) 
t1/2 HLM 
 (min) 
 
UCP1021 
 
 
0.21 
 
1.55 
 
31 
 
81 
 
UCP1031 
 
 
2.4 
 
N/A 
 
N/A 
 
N/A 
 
UCP1038 
 
 
<0.02 
 
0.07 
 
79 
 
270 
74 
 
 
UCP1040 
 
 
0.02 
 
1.65 
 
65 
 
87 
 
UCP1047 
 
 
0.17 
 
N/A 
 
N/A 
 
N/A 
 
UCP1052 
 
 
0.56 
 
>5.6 
 
68 
 
N/A 
 
UCP1055 
 
 
5.76 
 
>29 
 
101 
 
N/A 
 
UCP1061 
 
 
0.06 
 
N/A 
 
37 
 
100 
 
UCP1062 
 
 
0.02 
 
1.41 
 
37 
 
75 
 
75 
 
 
UCP1063 
 
 
0.05 
 
N/A 
 
135 
 
146 
 
 
UCP1064 
 
 
0.07 
 
N/A 
 
69 
 
135 
 
 
UCP1066 
 
 
0.45 
 
8.17 
 
24 
 
69 
 
 
UCP1067 
 
 
0.04 
 
N/A 
 
15 
 
 
N/A 
 
UCP1070 
 
 
0.04 
 
 
0.01 
 
91 
 
101 
 
UCP1072 
 
 
0.02 
 
N/A 
 
N/A 
 
N/A 
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UCP1074 
 
 
0.02 
 
 
N/A 
 
N/A 
 
N/A 
 
UCP1075 
 
 
<0.01 
 
 
0.16 
 
N/A 
 
N/A 
 
UCP1076 
 
 
3.65 
 
9.81 
 
35 
 
82 
 
 
UCP1077 
 
 
2.65 
 
 
13.21 
 
20 
 
 
340 
 
 
UCP1079 
 
 
0.21 
 
 
9.25 
 
 
260 
 
N/A 
 
 
UCP1080 
 
 
0.29 
 
3.82 
 
71 
 
N/A 
 
77 
 
 
UCP1082 
 
 
0.20 
 
 
2.54 
 
213 
 
N/A 
 
 
 
UCP1084 
 
 
<0.01 
 
 
N/A 
 
N/A 
 
N/A 
 
It is well accepted that compounds that contain the heme-ligating pyridine group are 
common CYP inhibitors [8].  UCP1075, UCP1076 and UCP1077 were designed to reduce 
the CYP inhibition potential with diminished heme binding by adding bulky hydrophobic 
groups on the exposed pyridine ring.  Surprisingly, UCP1075 exhibited even stronger CYP 
inhibition of both CYP3A4 (IC50<0.01 µM) and CYP2D6 (IC50=0.16 µM) compard to 
UCP1040 (CYP3A4 IC50=0.02 µM and CYP2D6 IC50=1.65 µM).  The 2’ methy substitution 
on the pyridine may have reduced the flexibility of the distal pyridine ring or enhanced 
the CYP binding with increased hydrophobicity, therefore resulting in a better fit the 
molecule into the CYP3A4 and CYP2D6 binding pocket and stronger CYP inhibition.  In 
contrast, dimethyl (UCP1076) and methoxy (UCP1077) protected pyridine significantly 
reduced both CYP3A4 (IC50=3.65 µM and IC50=2.65 µM) and CYP2D6 (IC50=9.81 µM and 
IC50=13.21 µM) inhibition.  UCP1031, featuring a single methyl protected pyridine, also 
shows weaker CYP3A4 inhibition (IC50=2.4 µM).  Despite the difference at the linker 
region and exposed phenyl B-ring, a single methyl group next to a pyridine nitrogen 
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atom seems to sufficiently reduce the heme binding propensity.  Overall, blocking the 
open distal pyridine with bulky hydrophobic functional groups next to the nitrogen atom 
seems a viable strategy to reduce CYP3A4 and CYP2D6 inhibition for propargyl-linked 
antifolates.  
Evidently, the improvement in CYP inhibition for UCP1076 and UCP1077 also associates 
with decreased metabolic half-life (t1/2=35 min and 20 mins, respectively).  A metabolite 
identification study of UCP1076 also suggested that the dimethyl protection eliminated 
pyridine N-oxdiation, one of the two predominant metabolic routes.  With major 
metabolic route blocked and decrease in microsomal stability, it implicates that the 
previous described metabolic improvement at high testing concentration may be an 
artificial effect from self inhibition of CYPs.  This is also consistent with in vivo PK testing 
results of UCP1006 and UCP1063 (chapter 6).  To justify this hypothesis, the metabolic 
half-life of lead compounds will be further evaluated at a lower concentration (0.5µg/mL) 
with MLM and HLM.   
 
7.3. Determine metabolic half-life at low testing concentration 
Single time point metabolic stability testing as previously described is a common 
experimental approach to rank order lead compounds [9].  Due to instrumental 
restraints, the more accessible HPLC-UV system poses a detection limit at ~0.5µg/mL.  
Therefore, the initial testing concentration was selected at 5 µg/mL.  CYP inhibition 
testing indicated that several lead compounds are potent CYP3A4 and CYP2D6 inhibitors.  
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Therefore, a more comprehensive metabolic half-life evaluation approach with lower 
compound testing concentration is needed.  To achieve low testing concentration 
detection, a UHPLC-MS bioanalytical method to quantify testing compounds in a time 
dependent manner was adopted. The new MS based detection limit can reach as low as 
10 ng/mL.  
Table 2. In vitro microsomal metabolic half-life of lead propargyl-linked DHFR inhibitors 
at 5 µg/ml and 0.5 µg/ml.  
 
Cmpd# 
 
Structure 
t 1/2 MLM 
@5µg/ml 
(min) 
t 1/2 MLM 
@0.5µg/ml 
(min) 
 
UCP1038 
 
 
79 
 
14 
 
UCP1063 
 
 
135 
 
14 
 
UCP1064 
 
 
69 
 
5 
80 
 
 
UCP1070 
 
 
91 
 
13 
 
UCP1076 
 
 
35 
 
8 
 
UCP1079 
 
 
260 
 
13 
 
UCP1080 
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Several lead compounds with promising metabolic half-life at 5 µg/ml were selected for 
metabolic stability testing at a lower concentration (Table 2.).  All the testing 
compounds exhibited a dramatic decrease in metabolic half-life at lower concentration 
(5~14 mins).  For example, UCP1063 showed a metabolic half-life of 14 minutes at 0.5 
µg/mL compared with 134 minutes at 5 µg/mL.  No difference in metabolic stability 
between UCP1038 and UCP1070 was observed; suggesting that the deuterium 
substitution on the dioxolane methylene group may have only slowed the reactive 
intermediate formation rather than increased the overall microsomal stability.  Two 
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pairs of single enantiomers were tested; UCP1063 and UCP1079 (both S-enantiomers) 
exhibited better metabolic stability compared to their R- enantiomers.  However, the 
margin of difference was relatively small and the mechanism is still to be determined.   
It is noticeable that the previously recognized improvement in metabolic stability was 
likely an artificial effect from the strong CYP inhibition and this improvement was not 
repeated when tested at a lower substrate concentration.  This also explained that 
UCP1063 had similar in vivo metabolic half-life and drug exposure compared to 
UCP1006, despite their significant in vitro half-life differences.  Even with one major 
metabolic route diminished, UCP1076 also showed a significantly shorter metabolic half-
life at lower concentration.  Taken together, blocking the primary metabolic route 
(pyridine-N-oxidation) of these propargyl-linked antifolates is not sufficient to greatly 
improve their overall intrinsic metabolic stability.  Therefore, further metabolism 
optimization to block multiple metabolic “soft spots” and decrease CYP binding through 
reducing hydrophobicity will be explored.  
7.4. Optimization of metabolic stability at lower testing concentration  
Previous CYP inhibition testing suggested that with the presence of the exposed pyridine, 
most lead compounds were potent CYP3A4 or CYP2D6 inhibitors.  With low testing 
concentrations of 0.5 µg/mL, phase I metabolic half-life of all lead compounds were 
equal or lower than 14 mins.  To further optimize the metabolic stability of lead 
propargyl-linked antifolates while minimizing the CYP inhibitory propensity, approaches 
to block the metabolism “soft spots” and decrease lipophilicity were implemented. 
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7.4.1 Increase metabolic stability using deuterated dioxolane and dioxane  
The early dioxolane compound UCP1038 exhibited potent antibacterial activity against 
MSRA (MIC=0.08 µg/mL).  However, it was also a strong CYP inhibitor with 100% CYP3A4 
inhibition at 0.02µM and IC50 values of 0.07 µM against CYP2D6.  Aiming to reduce the 
CYP inhibition, the deuterium substituted derivative UCP1070 was synthesized [10].  
Despite the improvement of CYP3A4 inhibition (IC50=0.04 µM), UCP1070 retained potent 
CYP2D6 inhibitory activity (IC50=0.01 µM).  To further investigate the mechanism of CYP 
inhibition of these dioxolane containing compounds and potentially develop better lead 
compounds, UCP1112 and UCP1114 were designed and synthesized (Fig 2.).   
 
Figure 2. Structure, MLM half-life and CYP inhibition activity of UCP1038, UCP1070, UCP1112 
and UCP1114.  
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As previously described, pyridine containing compounds are common CYP inhibitors due 
to the metal chelating activity and this CYP inhibition tendency can be weakened with 
hydrophobic decoration next to pyridine nitrogen atom.  Dimethyl pyridinyl substituted 
UCP1112 was designed to probe the CYP inhibition liability of deuterated dioxolane.  
Comparing to its pyridinyl analogue, UCP1112 exhibited over 500 fold reduction of 
CYP2D6 inhibition.  Surprisingly, UCP1112 remained a potent CYP3A4 inhibitor 
(IC50=0.01 µM).  Despite high structural similarity to the dioxolane, dioxane substituted 
UCP1114 showed only moderate CYP3A4 and CYP2D6 inhibition (IC50=4.5 µM and 16.9 
µM, respectively).  In addition, UCP1114 also characterized with high antibacterial 
potency with MIC value lower than 0.08 µg/mL against MRSA.  SPR analysis clearly 
illustrated that the strong CYP3A4 inhibition of UCP1038 is likely a result from 
bioactivation of benzyl dioxolane to carbene and subsequently covalent interaction to 
the heme group from CYPs.  The deuterium effects on the dioxolane methylene 
(UCP1070) effectively reduced this quasi-irreversible interaction and therefore 
decreased CYP3A4 inhibition was observed.  With a protected pyridine, UCP1112 had a 
CYP3A4 IC50 of 0.01 µM, which suggested even the mechanism-based inactivation of 
benzyl dioxolane was dwindled by deuterium effects, likely strong non-covalent 
interactions still resulted in potent CYP3A4 inhibition.  The moderate CYP3A4 and 
CYP2D6 inhibition of UCP1114 also supported this hypothesis.  Despite the promising 
antibacterial activity and encouraging CYP inhibition values, UCP1114 was quickly 
metabolized by MLM.  Additional metabolite identification studies will be important to 
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understand the metabolism routes and further improvement of metabolic stability is 
warranted.    
7.4.2 Improve metabolic half-life by blocking demethylation 
Lead compounds containing a 2’ or 3’ methoxyl group on the adjacent phenyl (UCP1006, 
UCP1063 and UCP1076, etc) were excellent antibacterial agents against MRSA.  
However, previous studies indicated poor metabolic stability.  To eliminate the 
demethylation, one of the primary biotransformation routes, and potentially increase in 
vitro microsomal half-life, several UCP1076 analogues were synthesized.   
 
Figure 3. Structure, MLM half-life and CYP inhibition activity of UCP1076, UCP1111 and UCP1115.  
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Metabolite identification results suggested the only major metabolic route of UCP1076 
was through demethylation on the 2’ position of the adjacent phenyl ring.  The 
deuterium substituted derivative UCP1111 was designed to reduce this reaction with a 
more rigid C-D bond [11-12].  Little effect of increasing metabolic half-life was observed 
(8 and 9 minutes), while the IC50 values against CYP3A4 increased from 3.7 µM to 11.0 
µM.  Therefore, the deuterium substitution seems to not be strong enough to drastically 
slow the demethylation. In the mean time, UCP1111 derivative with trifluoro methoxy 
or fluorine substitutions were under development.  Additionally, UCP1115 with an 
unsubstituted adjacent phenyl group showed marginal improvement with MLM (half-life 
of 20 mins); however, stronger CYP3A4 inhibition (IC50=0.5 µM) was also detected.  
Hydroxylation on the phenyl ring is likely the primary metabolic route for UCP1115, a 
detailed metabolite identification assessment will be performed and the hydroxylation 
position will be assigned with LC-MS/MS.  Analogues with reduced benzyl hydroxylation 
will be synthesized and evaluated.  
7.4.3 Optimize microsomal stability through reducing hydrophobicity 
Decreased hydrophobicity usually reduces the binding of small molecule drugs to 
cytochrome P450s and therefore increases metabolic stability [13].  Previously 
described crystallographic insight of lead propargyl-linked DHFR antifolates bound to 
SaDHFR revealed the para and meta positions of the distal phenyl ring are solvent 
exposed and may tolerate polar substitutions.  Two new compounds with hydrophilic 
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functional groups on the distal rings were therefore synthesized with the goal of 
prolonging metabolic half-life.   
 
Figure 4. Structure, LogD values, MLM half-life and CYP inhibition activity of UCP1104 and 
UCP1106. 
 
UCP1104 and UCP1106, features pyridone and benzoic acid functional group at the 
distal biaryl system respectively, decrease LogD values at pH7.4 (2.57 and 1.44) 
compared to their pyrdine analogue (UCP1040 logD7.4=3.44).  With a pyridone group, 
UCP1104 shows small improvement in metabolic half-life of 16mins and potent CYP3A4 
inhibition (IC50=0.8 µM).  A low CYP2D6 inhibition value was also observed (IC50=34.6 
µM).  More excitingly, UCP1106, the zwitterion compound with a carboxylic acid at the 
meta position of the distal phenyl ring highlighted excellent ADME properties with MLM 
half-life of 99 mins, IC50 values against CYP3A4 and CYP2D6 both greater than 50µM (31% 
CYP3A4 inhibition and less than 5% CYP2D6 inhibition at 50 µM).  In addition to its 
superb PK properties, UCP1106 also proved to have exceptional antibacterial activity 
(MIC=0.16 µg/mL) against MRSA.  As the best lead compound so far, thorough 
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metabolite identification evaluation will be conducted and in vivo PK and efficacy 
assessment will also be performed.   
7.5. Conclusions 
Drugs that inhibit cytochome P450s may interfere with the PK profiles of other drugs co-
administered and often cause drug-drug interactions.  Pyridines containing lead 
propargyl-linked antifolates were confirmed potent inhibitors against CYP3A4 and 
CYP2D6.  The strong CYP inhibition was also hypothesized to artificially prolonged the in 
vitro microsomal half-life tested with high substrate concentration.  Further metabolic 
stability assessment with MLM using testing concentrations of  at 0.5 µg/mL revealed 
dramatic decrease in half-life.   
To diminish the CYP inhibition propensity and block metabolic soft spot, which may 
potentially increase in vitro microsomal stability, several approaches were implemented.  
A series of lead compounds with dimethyl protected pyridine functionality at the distal 
position were designed and synthesized.  The hydrophobic groups next to the pyridyl 
nitrogen effectively reduced the non-specific metal chelating activity of pyridine 
resulting in decreased CYP inhibition liability.  In addition, this modification also 
completely blocked pyridine N-oxidation, the primary biotransformation route of early 
propargyl-linked DHFR inhibitors.  Despite the promising improvement of new lead 
compounds, their metabolic stability was still poor.  UCP1115, the most stable lead in 
this series, has a 20 minute half-life with MLM.  Thorough metabolite identification 
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evaluation will be performed and analogues with improved microsomal stability will be 
designed.  
Another strategy to decrease CYP binding by reducing hydrophobicity was also explored.  
UCP1106, a zwitterion compound featuring a carboxylic acid group on the meta position 
of distal phenyl ring. This compound exhibited excellent ADME properties with MLM 
t1/2=99 min and IC50 values of greater than 50 µM for both CYP3A4 and CYP2D6.  In 
addition, UCP1106 also showed potent antibacterial activity with MRSA (MIC=0.15 
µg/mL).  As the best lead compound so far, UCP1106 will be further investigated.   
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Chapter 8 
In vitro PK properties of tropolone analogues assessment 
8.1. Introduction 
Hinokitiol (β-thujaplicin) (Fig 1.) is a natural product found in the heartwood of 
cupressaceous plants [1].  2-hydroxy tropone (tropolone) (Fig 1.) is the prominent 
functional group in hinokitiol.  Biological functions of tropolone derivatives include 
antibacterial [2], antiviral [3] and anticancer activities [4].  Strong metal chelation has 
been observed in tropolone analogues and is likely responsible for the various 
antiproliferative properties [5].  Unlike most natural products, hinokitiol is low 
molecular weight (MW=164), which allows extensive structural modification as a drug 
scaffold.  A small library of tropolone analogues with substitutions at both α and β 
positions has been designed and synthesized in the Wright lab [6].  These tropolone-
based compounds exhibit promising selective histone deacetylase (HDAC) enzymatic 
inhibition [7-8]. 
HDACs are responsible for deacetylating the amino-terminal tails of histones [9] using a 
zinc-catalyzed reaction.  Abnormal recruitment of HDAC has been proved to be a key 
pathogenetic mechanism of acute promyelocytic leukemia (APL) [10].  The HDAC 
inhibitor vorinostat (Fig 2.) featuring a zinc-targeting hydroxamate group was approved 
by FDA for treatment of cutaneous T-cell lymphoma [11].  Lead compounds in the 
tropolone based HDAC inhibitor library display promising HDAC inhibition activity and 
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selectivity for HDAC2.  Some lead compounds were also found to be highly potent 
against various T-cell lymphocyte cell lines [7]. 
 
Figure 1. Structure of hinokitiol, tropolone and vorinostat. 
 
8.2. HDAC inhibition and cytotoxicty of lead Tropolone analogues 
Lead compounds alpha-phenyl tropolone and beta-phenyl tropolone (Fig 2.) both 
exhibited potent and selective HDAC-2 (IC50=0.29 nM and 0.06 nM) and HDAC-8 
inhibition (IC50=1.09 nM and 1.47 nM) [7].  Promising anticancer activities were also 
observed in T-lymphocyte cancer cell line (Jurkat cells) with minimal cytotoxicity with 
non-malignant human dermal fibroblast line (hDF cells).   
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Figure 2. Structure and activity of alpha-phenyl tropolone and beta-phenyl troplone. 
 
A recent study on the antiproliferative properties of tropolone analogues towards Jurkat 
cells suggested that similar to vorinostat, alpha-phenyl tropolone induced perforin 
overexpression and activated caspase-3/7.  In contrast, alpha-phenyl tropolone 
modestly inhibited hyperacetylation and did not induce p21 overexpression.  In addition, 
cell cycle arrest patterns from alpha-phenyl tropolone and vorinostat also appear 
different.  Taken together, alpha-phenyl tropolone induced apoptosis of Jurkat cells 
through a mechanism distinct from vorinostat [8].  
8.3. In vitro ADME property evaluation of lead tropolone analogues 
To characterize the drug likeliness of tropolone analogues and potentially rank order 
compounds with better PK properties, kinetic solubility, Phase I and Phase II metabolic 
half-lives were evaluated with MLMs for key lead compounds.   
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8.3.1 Metabolic stability assessment of alpha-phenyl tropolone 
Due to the strong metal chelating property, detection of unprotected tropolone 
analogues through HPLC fitted with reverse-phase columns is extremely difficult.  Lead 
compound alpha-phenyl tropolone and its isomer beta-phenyl tropolone both tend to 
interact with the silico bead from C-18 column nonspecifically and cannot be eluted or 
generate strong tailing peaks, which are impossible to quantify. Multiple mobile phase 
and columns were tested. A protocol using both acid modifier (trifluoroacetic acid up to 
0.1%) and metal chelating agent (acetylacetone up to 0.1%) were developed.  
 
Figure 3. Structure of protected alpha-phenyl tropolone 
 
Alpha-phenyl tropolone, the most potent lead against various T-lymphocyte cancer cell 
lines, exhibits high metabolic stability with phase I half-life of 93mins and phase II of 60 
mins.  In contrast, the inactive version methoxyl-protected version of alpha-phenyl (Fig 
3.) showed significantly faster metabolism with phase I half-life at 13 mins.  Detailed 
metabolite identification is needed to thoroughly understand the metabolism of these 
tropolone analogues. 
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8.3.2 Solution solubility determination of alpha-naphthyl tropolone 
With the evolution of tropolone analogues, a newer lead compound alpha-naphthyl 
tropolone exhibited promising cytotoxicity against various malignant cell lines.  To 
assess the drug likeliness of these compounds and prepare for in vivo efficacy testing, 
kinetic solubility of the alpha-naphthyl tropolone was evaluated in water, RPMI medium 
and phosphate buffered saline (PBS).  The calculated logD value at pH7.4 was 3.16 (Fig 
4., estimated by software ChemAxon).  The experimental solubility was determined as 
240 µM in PBS and water, while significantly lower at 80 µM in RPMI medium.  The 
solubility discrepancy was hypothesized to be due to ion strength or composition 
difference in buffer; however, thorough evaluation will be performed in the future.  
Lead compounds with better solubility are under preparation.  
 
Figure 4. Structure and calculated logD value of alpha-naphthyl tropolone 
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8.4. Conclusions 
A small library of tropolone based analogues was developed.  These tropolone 
compounds exhibit promising HDAC inhibition and cytotoxicity to T-lymphocyte cancer 
cell lines.  Initial ADME evaluation also suggested lead compound alpha-phenyl 
tropolone was more metabolically stable than the FDA approved hydroxamate 
containing HDAC inhibitor vorinostat.  A detailed mechanic study revealed an anti-
proliferative manner distinct from vorinostat [8].  Newer tropolone-based compounds 
with potent inhibition of the growth of hematological cell lines and better drug likeliness 
are under development.   
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Chapter 9 
Summary and future directions 
9.1. Summary of work 
Dihydrofolate reductase (DHFR) is a key enzyme in the folate biosynthetic pathway and 
has been a popular drug target for over sixty years [1-3].  TMP is the sole FDA approved 
antibacterial DHFR inhibitor and remains clinicalally important [4-5].  However, acquired 
resistance by point mutations and natural enzymatic insensitivity limit its use [6-9].   
During the past several years, a novel class of propargyl-linked DHFR inhibitors targeting 
MRSA, Candida and Klebsiella species was developed under the robust collaboration 
between Drs. Amy Anderson and Dennis Wright [10-13].  Early lead compounds in this 
library exhibit potent enzyme inhibition and promising antibacterial and antifungal 
activities [14-15].  Initial ADME assessment suggested some compounds were poorly 
water soluble and metabolically instable [16].  To improve the drug likeliness while 
maintaining high antimicrobial potency, a strategy of incorporating crystallographic 
insight and experimental evaluation of SAR to guide new compound generation was 
explored.   
UCP111D, a lead compound within the biphenyl series, exhibited potent inhibition of S. 
aureus DHFR (IC50=61 nM) and promising antibacterial activity (MIC=0.72 µg/mL) [14].  
However, low water solubility (20 µg/mL) and precipitation in DMSO stock was also 
observed.  Much effort was taken to improve the water solubility by introducing more 
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polar functional groups.  UCP1006, featuring a pyridine substitution at the distal biaryl 
system, was synthesized and showed improved solubility (40 µg/mL) and striking 
antibacterial activity (MIC=0.08 µg/mL).  A study of the metabolic stability of UCP1006 
and its derivatives suggested a relatively short half-life with MLM.  SPR analysis also 
indicated that the metabolic stability of these analogues was sensitive to substitutions 
at the propargylic and adjacent aryl methoxy positions.  UCP1040, featuring a propargyl 
methyl and 2’ methoxy group on the adjacent phenyl ring, showed increased metabolic 
half-life of 65mins at high substrate testing concentration.     
To thoroughly investigate the DMPK properties of lead propargyl-linked compounds, 
multiple in vitro and in vivo assays were performed.  Some early pyridine containing 
compounds were found to be strong CYP3A4 and CYP2D6 inhibitors.  It was also 
hypothesized the prolonged in vitro microsomal half-life detected at the high substrate 
concentration were artificial effects from inhibition of CYP isoforms responsible for its 
own metabolism.  Metabolic stability evaluation using lower substrate concentration 
(0.5 µg/mL) resulted in dramatically shorter half-lives.   
To further improve metabolic stability while reducing the propensity for CYP inhibition, 
two approaches were implemented: one, blocking the metabolic “soft-spots” and 
preventing metabolite formation; two, decreasing the hydrophobicity of the compounds, 
thereby reducing CYP binding.  Dimethyl pyridine substituted UCP1076 effectively 
diminished the primary metabolism route of pyridine-N-oxidation.  In addition, the 
protected pyridine group also sharply decreased CYP3A4 inhibition by 80 folds.  
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However, the metabolic half-life of UCP1076 remained short (8 mins).  A metabolite 
identification study suggested the only major metabolic route for UCP1076 was 
demethylation on the 2’ methoxy group on the adjacent phenyl ring.  Several attempts 
were made to improve microsomal stability by introducing a deuterium substituted 
methoxy group, dimethoxy, dioxolane or dioxane on the adjacent phenyl ring.  However, 
little effect was observed.  UCP1115, featuring an open phenyl on the adjacent position 
and a distal dimethyl pyridine, exhibited marginal improvement with a half-life of 20 
minutes with MLM.  Detailed metabolite identification and optimization of UCP1115 
was under investigation.          
UCP1106, a zwitterion compound featuring a carboxyl phenyl on the distal position with 
a propargylic hydrogen and 2’ methoxy on the adjacent phenyl ring, was designed to 
improve metabolic stability with lower hydrophobicity.  UCP1106 exhibited excellent 
ADME properties with t1/2=99 mins against MLM and low inhibition for CYP3A4 and 
CYP2D6 (IC50 greater than 50 µM).  Furthermore, UCP1106 was also proven to be a 
potent S. aureus inhibitor (MIC=0.02 µg/mL).  More recent results also suggested that 
UCP1106 has low toxicity to mammalian cell lines.  As the best lead compound so far, 
the in vivo PK properties and efficacy will be evaluated.  
9.2. Future plans 
9.2.1 Lead optimization of dimethyl pyridine series 
Lead propargyl-linked antifolates featuring a distal dimethyl pyridine functional group 
(UCP1076, UCP1111, and UCP1115 etc.) are potent antibacterial agents.  The 
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microsomal stability of these compounds is general low (t1/2 between 8 to 20 mins), and 
initial metabolite identification assessment suggested the primary metabolic route was 
demethylation or hydroxylation on the adjacent phenyl ring (data not shown).  Several 
new compounds are designed aiming to increase the in vitro metabolic half-life while 
maintaining high antibacterial and low CYP inhibition activity.   
a.                                                      b.                                                      c. 
 
Figure 1. Structures of proposed dimethy pyridine compounds 
 
UCP1117 (Fig 1a.), featuring a 2’ trifluoromethoxy group on the adjacent phenyl, is 
proposed with similar DHFR inhibitory activity and low CYP inhibition as its 
trideuteromethoxy analogue (UCP1111).  In addition, it is also generally believed that 
the fluorine substitution will also effectively diminish the demethylation route from 
cytochrome P450s [17-18].  With the only major metabolism route blocked, a 
significantly longer metabolic half-life is expected for UCP1117.   
UCP1119 (Fig 1b) and UCP1120 (Fig 1c), featuring 2’ chlorine and 3’ fluorine on the 
adjacent phenyl ring, respectively, are also hypothesized to be potent antibacterial 
agents with promising ADME properties.  With the major metabolite of UCP1115 
tentatively assigned as hydroxylation on the adjacent phenyl ring, the blocking group 
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from the two new compounds should efficiently reduce the metabolism [19-21].  The 
electron withdrawing propensity of the halogen atoms may also contribute to decrease 
the strong CYP3A4 inhibition liability observed in UCP1115 (IC50=0.5 µM).   
These three compounds are all racemic mixtures with a chiral center at the propargylic 
position.  Previous results suggested that the stereo chemical configuration at the 
position is important to both antibacterial potency and metabolic fate.  Therefore, 
generation of the single enantiomers would be useful.  It would be interesting to 
experimentally evaluate the in vitro ADME properties of these proposed compounds.  
With the expected improvement in microsomal stability, the in vivo drug exposure and 
residence time would also increase.  Establishment of the in vitro and in vivo correlation 
of ADME properties would help better rank order compounds and selection for more 
comprehensive in vivo efficacy study using infected animal models.   
9.2.2 Lead optimization of dioxolane series 
Lead compounds featuring benzyl dioxolane at the adjacent biaryl system (UCP1038, 
UCP1070, and UCP1112 etc) are excellent antibacterial agents.  UCP1070 and UCP1112 
both highlight a deuterated dioxolane methylene group.  Despite the protection of 
mechanism based inaction of CYPs, the two compounds remained strong CYP3A4 
inhibitors and the metabolic half-life of the compounds in the dioxolane series is still 
short.  Metabolite identification results indicated that the major metabolic route was 
hydroxylation on the dioxolane ring, subsequently generating dihydroxy phenyl 
metabolites.  It is hypothesized that a fluorine substituted dioxolane (Fig 2a) on the 
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methylene group would completely block this reaction.  It would be also valuable to 
understand if the fluorine substitution would also reduce the CYP3A4 inhibition.     
              a.                                                         b.                                               c. 
Figure 2. Structures of proposed dioxolane and zwitterions compounds 
 
9.2.3 Lead optimization of zwitterion compounds series 
UCP1106, a zwitterion compound featuring a distal benzoic acid on the biaryl system, 
exhibited superb antibacterial activity.  In vitro ADME assessment also revealed superior 
metabolic stability, water solubility and low CYP inhibition.  Initial assessment also 
suggested moderate toxicity to mammalian cell lines.  Collectively, UCP1106 was the 
best compound in the library of propargyl-linked antifolate.  In vivo PK and efficacy of 
UCP1106 will be thoroughly investigated.  If an unexpected ADME liability was observed 
in vivo, possible derivatives of UCP1106 like benzamide (Fig 2b) or sulfonic acid (Fig2c) 
would be suitable alternatives.  Previously described compounds in the para series were 
more active against Candida glabrata and Candida albicans[13], it is also advised to 
evaluated para-substituted versions of UCP1106 analogues for antifungal activities.   
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9.2.4 In vivo efficacy evaluation strategy 
Through collaboration with Dr. Wielderhold’s group in UTHSCSA, the in vivo 
antibacterial activity of UCP1006 was evaluated using a well characterized mice MRSA 
bacteremia model [22-23].  Although the compound did not effectively clear the 
bacterial infection, lessons were learned to better support the development of the 
antifolates.   
With the improvement of in vitro metabolic stability and decrease in CYP inhibition, 
better in vivo drug exposure and less CYP induction are expected for newer lead 
compounds (UCP1106, UCP1117 etc.).  More excitingly, the new compounds also 
exhibited better antibacterial potency and lower mammalian cell toxicity.   Therefore, a 
possibly higher dosage would be tolerated and a higher drug concentration would be 
expected in targeted tissues.  While the high thymidine level in murine plasma would be 
expected to bypass the DHFR inhibition and compromise the antibacterial activity of 
antifolates [24-25], a side-by-side in vivo efficacy study using a thymidine kinase (TK) 
knockout MRSA strain would be helpful to prove potency.  In addition, to assess future 
efficacy for pathogens without TK knockout strains (Candida or klebsiella spp), a possible 
alternative strategy is to pre-treat animals with pegylated thymidine phosphorylase, 
which would reduce the circulating thymidine level to that similar to human during the 
treatment period [24].    
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Chapter 10 
Materials and methods 
10.1. Metabolic stability determination [1] 
10.1.1 High-performance liquid chromatography analysis 
 A Shimadzu Prominence 20 high-performance liquid chromatography (HPLC) 
instrument (Shimadzu, Kyoto, Japan) fitted with a Luna 5 µm C18 (2) 100 Å column (5 
µM, 4.6 X 250 mm; Phenomenex, Torrance, CA) and a UV diode array detection at 254 
nm was used to quantify compounds at 1µg/mL or above. The mobile phase consisted of 
50% acetonitrile (ACN) and 50% potassium phosphate buffer (50 mM, pH 7.0), using an 
isocratic flow rate of 1.5 mL/min. 
10.1.2 Metabolic half-life determination at high substrate concentration 
Compounds were incubated with mouse liver microsomes or human liver microsomes 
(MLM or HLM; BD Biosciences, San Jose, CA) in 0.1 M potassium phosphate buffer (pH 
7.4) and 200 µg/ml HPMC A4M in the presence of an NADPH regenerating system at 
37°C. The final concentrations of inhibitor, microsomes, NADPH+, glucose 6-phosphate, 
glucose-6-phosphate dehydrogenase, and MgCl2 were 5 µg/mL, 0.5 mg/mL, 1.3 mM, 3.3 
mM, 0.5 U/mL, and 3.3mM, respectively. DMSO and compounds without MLM were 
used as negative controls. The reactions were initiated by the addition of microsomes 
and quenched by the addition of an equal volume of ice-cold ACN after 60 or 120 min. 
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The samples were subjected to centrifugation at 15,000 rpm for 10 min. 100µL of the 
diluted sample was injected on to the HPLC reversed-phase column.  The concentration 
of compounds before and after metabolic incubation was calculated by standard curves 
obtained with each compound.  Standard curves were performed multiple times and 
showed intraday and interday CV of less than 5%.  To compare the metabolic stability of 
different compounds, the percentage of the parent compound remaining after 
incubation as compared with the amount before incubation was calculated.  The in vitro 
metabolic half-life was calculated using a single time point approach following first-
order kinetics as described previously. 
10.1.3 Metabolic half-life evaluation and LC-MS analysis 
A Shimadzu UPLC system equipped with LC-30AD gradient pump, CTO-30A column oven, 
CBM-20A UFLC coordinator, Prominence DGU-20A5 degasser and SIL-20AC auto-
sampler was used for separation.  Mass spectrometry was performed on a Shimadzu 
LCMS2020 system equipped with both electrospray ionization (ESI) and atmospheric-
pressure chemical ionization (APCI) source.  LC separation was achieved with a 
Phenomenex Kinetex 1.7µm C18 100Å column.  Mobile phase A, consisting of 0.01% 
heptafluorobutyric acid (HFBA) in water, and mobile phase B, consisting of 0.01% HFBA 
in ACN, were used for a binary gradient elution as follows: 5 to 95% B in 7mins, hold at 
95% B for 2mins, 95 to 5% B in 1min and hold at 5% B for 2mins.  Diltiazem (500ng/mL) 
was used as internal control (IC).   
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MS was performed in the positive ion mode with EPI and APCI duel ionization mode.  
The interface temperature was set at 350°C, DL temperature was 250°C, nebulizing gas 
flow 1.5l/min, heat block temperature 400°C and drying gas flow at 15l/min.  The 
analytes and IC were monitored at both scan mode and selected ion monitoring (SIM) 
mode.  The scan mode was set from 50 to 500 m/z with scan speed 15000 u/sec and 
event time at 0.05sec.   
The incubation condition was the same as described above expect the compound 
concentration was 0.5µg/mL.  The reaction was initiated by the addition of microsomes. 
100µL samples were withdrawn from mixture at 0, 10, 20, 30, 40 and 60 minutes after 
the start of incubation and protein precipitation was achieved by adding 100µL of ice 
cold ACN.  The samples were subjected to centrifugation at 15,000 rpm for 10 min. 3 to 
5µL of the supernatant was injected on to the UPLC-MS.  The detection limit was 
estimated as 10ng/mL.  The in vitro metabolic half-life was calculated using a multiple 
time points approach following first-order kinetics.   
10.2. Kinetic solubility assay 
Compounds were initially dissolved as 20 or 40 mg/mL dimethyl sulfoxide (DMSO) 
solutions and diluted in filtered water in the presence of 200 µg/mL methylcellulose 
(METHOCEL A4M; Dow Corning, Midland, MI).  All samples were centrifuged for 10 min 
at 15,000 rpm, incubated at room temperature for 30 min, and analyzed by reversed 
phase HPLC-UV. Solubility was determined as the maximal concentration for which 
absorption is linearly related to the log of the concentration [2]. 
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10.3. Solution stability assay 
Compounds at 5 µg/mL were incubated with water, simulated gastric fluid and 
simulated intestinal fluid at 37°C for 24 h. All solutions contained 200 µg/mL 
hydroxypropylmethylcellulose (HPMC) A4M.  Samples were collected before and after 
incubation.  Assays were terminated by adding an equal volume of ice-cold ACN and 
centrifuging at 15,000 rpm for 10 min. One hundred microliters of supernatant was 
injected on the reversed-phase column of the HPLC-UV; solution stability was calculated 
using a ratio of area under the curve (AUC) (after incubation)/AUC (before incubation) 
[3]. 
10.4. Membrane permeability evaluation  
Membrane permeability of propargyl-linked antifolates was evaluated with a PAMPA 
assay using CentrifreeTM ultrafiltration devices from Millipore (Billerica, MA).  30, 000 
MWCO regenerated cellulose was selected.  Testing compounds at 200 µM in PBS (1 mL 
total volume) was added into the sample reservoir.  The devices were then capped and 
centrifuged at 2, 000 g using a fixed-angle centrifuge rotor with 17 X 100 mm adapters 
for 15 min.  The filtrate cups were then removed and the ultrfiltrates were quantified by 
UV plate reader at 254 nm.   
10.5. Metabolite identification assay 
To identify phase I metabolites, compounds at 2 or 10µg/mL were incubated with MLM 
or HLM in the setup similar as described above.  To identify both phase I and phase II 
110 
 
metabolites, compounds (at 2 µg/mL) were incubated with mouse or human S9 
fractions in a Tris-HCl (pH7.5) buffer and 200 µg/mL HPMC A4M in the presence of an 
NADPH regenerating system and a UGT reaction mix for 2 hours at 37°C.  The final 
concentrations of inhibitor, microsomes, NADPH+, glucose 6-phosphate, glucose-6-
phosphate dehydrogenase, MgCl2, alamethicin, and UDPGA were 5 µg/mL, 0.5 mg/mL, 
1.3 mM, 3.3 mM, 0.5 U/mL, 8mM, 25 µg/mL and 2mM, respectively.  Negative controls 
included 1) using the same volume of DMSO or 2) quenching the reaction with ACN 
immediately after adding microsomes or S9 fractions.  Both samples and negative 
controls were incubated for 2 h, and the reaction was terminated with an equal volume 
(or 2X volumes for S9 fractions) of ice-cold ACN.  After removal of protein precipitates 
by centrifugation, supernatant phase was purified using Oasis hydrophilic-lipophilic 
balanced sample extraction cartridges (Waters, Milford, MA) following the 
manufacturer’s protocol.  Methanol (1 mL) was used to elute the sample, which was 
further diluted 2-fold with water above. 
10.6. Liquid chromatography/tandem mass spectrometry analysis and metabolite 
identification 
An Agilent 1100 HPLC system fitted with a Zorbax-C18 (3µm, 1.0X150 mm) (Agilent 
Technologies, Santa Clara, CA) was used for separation.  Mobile phase A, consisting of 
0.01% heptafluorobutyric acid in water, and mobile phase B, consisting of 0.01% 
heptafluorobutyric acid in ACN, were used for a linear gradient elution as follows: 0 to 
100% B in 17 min and isocratic hold at 100% B for 5 min. The flow rate was 75 µL/min, 
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and the injection volume was 8 µl.  Mass spectrometric detection was performed on a 
Micromass Q-Tof-2 mass spectrometer from Waters, equipped with an electrospray 
ionization source.  The mass spectrometer was operated in the positive ionization mode 
and was calibrated with Glu1-fibrinopeptide B on each experiment day.  Capillary 
voltage and cone voltage were set at 3000 and 20 V, respectively.  Source and 
desolvation temperatures were 100 and 150°C. 
Nitrogen was used as a desolvation gas at a flow rate of 450 mL/h.  Full-scan time-of-
flight spectra were first acquired for parent compounds and metabolites in the mass 
spectrometry mode.  Subsequently, collision-induced dissociation (CID) fragmentation 
spectra were obtained on the isolated protonated molecular ion of parent and 
metabolites in the tandem mass spectrometry mode.  Argon or nitrogen was used as the 
collision gas, and the collision energy was optimized for each compound in the range of 
20 to 40 eV.  Accurate mass was calculated using fragments of the coanalyzed 
calibration standard lisinopril as described previously [4].  The distribution of 
metabolites was calculated by dividing the AUC of the individual metabolite by the total 
AUC for all metabolites within the same injection. 
To achieve multiple-stage mass spectrometry (MSn), additional metabolite identification 
work was conducted at Proteomics center at Yale school of medicine (New Haven, CT) 
with the help of Dr. Tukiet Lam. Samples were anlyzed using an Acquity Ultra 
Performance LC system (Waters) fitted a Restek Ultra AQ C18 column (3 µm, 100 mm X 
1.0 mm, particle size 3 µm) connected with a LTQ orbittrap XL mass spectrometer from 
112 
 
Thermo Scientific [5].  Resolution was set at 30,000.  The collision energy was set at 
35eV with helium as collision gas.  Full scan range was set at 200~2000.   
The LC condition of mobile phase A, consisting of 0.01% heptafluorobutyric acid in water, 
and mobile phase B, consisting of 0.01% heptafluorobutyric acid in ACN, were used for a 
linear gradient elution as follows: 0 to 100% B in 17 min and isocratic hold at 100% B for 
5 min, additional 8 min was allowed to re-equilibrate column.  The flow rate was 
75µL/min, and the injection volume was 8 µL.   
Metabolism samples were prepared in house as described earlier and shipped to Yale 
for analysis.  Experimental results were then sent back for further data process using 
software Mass++ 64-bit version 2.7.2 (supported by Shimadzu Corporation and Eisai Co., 
Ltd).   
10.7. CYP inhibition assay 
CYP3A4 and CYP2D6 inhibition was evaluated using a commercial fluorescence based 
high-throughput screening assay from BD Gentest (Worcester, MA) [6-7].  For CYP3A4 
and CYP2D6, substrates BQ and AMMC were used generating fluorescent metabolites 
HQ and AHMC, respectively.  Compounds were tested in the range 0.008µM-50uM.  
Incubation was initiated by adding Supersome enzymes and terminated by adding stop 
solution after 30min incubation.  The IC50 values were calculated following a first order 
kinetics.     
10.8. Plasma drug quantification by UPLC-MS 
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All plasma samples from in vivo efficacy study were removed from -80°C and thawed at 
room temperature.  A 100µL sample was removed from each tube and mixed with 200 
µL ice cold ACN.  The samples were thoroughly mixed and centrifuged at 15,000 rpm for 
10mins.  The supernatants were then collected and analyzed by UPLC-MS.  Diltiazem 
was used as internal control.  The instrument setup was the same as described in 
section 10.1.3.  PK data was processed by WinNonlin (Pharsight Corporation) using a 
one compartmental IV-bolus model.   
10.9. Metabolic stability assay for tropolone analogues[8] 
The Incubation conditions for the tropolone compounds was the same as described in 
section 10.1.2 expect that the substrate concentration was 1µM.  The UPLC-MS assay 
used to quantify tropolone compounds was performed using the same mass 
spectrometer setup as described in the previous section (10.1.3).  The LC condition used 
for tropolone compounds specifically was mobile phase A, consisting of 0.01% 
acetylacetone (ACAC) and 0.1% TFA in water, and mobile phase B, consisting of 0.01% 
ACAC and 0.1% TFA in ACN, with a binary gradient elution as follows: 5 to 95% B in 
7mins, hold at 95% B for 2mins, 95 to 5% B in 1min and hold at 5% B for 2mins.  The in 
vitro metabolic half-life was calculated using a single time point approach following first-
order kinetics as described previously [2].  The detection limit was estimated as 
50ng/mL.   
10.10. Solution kinetic solubility assay for tropolone analogues 
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Tropolone compounds were initially dissolved as 100mM in DMSO solutions and diluted 
in filtered water, RPMI medium and phosphate buffered saline (PBS).  All samples were 
incubated at room temperature for 30 min, centrifuged for 10 min at 15,000 rpm, and 
analyzed by reversed phase HPLC as described in section 10.1.  The mobile phase 
consisted of 80% ACN and 20% potassium phosphate buffer (50 mM, pH 2.0), with 0.05% 
ACAC using an isocratic flow rate of 1.5 mL/min.  Solubility was determined as the 
maximal concentration for which absorption is linearly related to the log of the 
concentration. 
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Appendix 
Chapter 4.  
a. 
 
b. 
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c.  
 
d. 
 
e. 
 
Figure 1. a, MS full scan of compound 2 (UCP1005) and metabolites; b, c, d, e, MS/MS 
spectrum of compound 2, M2-1, M2-2 and M2-3 (shown as Chapter 4, Fig 5.).  
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d.  
 
e. 
 
Figure 2. a, MS full scan of compound 7 (UCP1015) and metabolites; b, c, d, e, MS/MS 
spectrum of compound 7, M7-1, M7-2 and M7-3 (shown as Chapter 4, Fig 5.).  
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d. 
 
e. 
 
Figure 3. a, MS full scan of compound 8 (UCP1021) and metabolites; b, c, d, e, MS/MS 
spectrum of compound 8, M8-1, M8-2 and M8-3 (shown as Chapter 4, Fig 5.).  
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f. 
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g. 
 
Figure 4. a, MS full scan of compound 10 (UCP1040) and metabolites; b, c, d, e,f, g, 
MS/MS spectrum of compound 10, M10-1, M10-2, M10-3, M10-4 and M10-5 (shown as 
Chapter 4, Fig 5.).  
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c. 
 
d. 
 
Figure 1. a, MS/MS spectrum of UCP1076; b, c, d, MS3 spectrum of UCP1076 daughter 
ions at m/z=387.29, 264.23 and 240.27, respectively.  
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c.  
 
Figure 2. a, MS/MS spectrum of demethylation metabolite of UCP1076; b, c, MS3 
spectrum of daughter ions at m/z=373.22 and 226.18, respectively.  
 
a. 
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b. 
 
Figure 3. a, MS/MS spectrum of glucuronidation metabolite of UCP1076 (structure 
shown in Chapter 5. Fig 10); b, MS3 spectrum of daughter ions at m/z=388.27.  
 
 
 
 
